17. Literaturverzeichnis – Hodgkin Lymphom

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften - Ständige Kommission, Leitlinien, AWMF-Regelwerk "Leitlinien", 1. Auflage 2012. 09.12.2013:, http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html

2. Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et.al. GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 2011. 64: p. 401-6., https://www.ncbi.nlm.nih.gov/pubmed/21208779

3. Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., et.al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias), J Clin Epidemiol, 2011. 64: p. 407-15., https://www.ncbi.nlm.nih.gov/pubmed/21247734

4. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency, J Clin Epidemiol, 2011. 64: p. 1294-302., https://www.ncbi.nlm.nih.gov/pubmed/21803546

5. Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., et.al. GRADE guidelines 6. Rating the quality of evidence--imprecision, J Clin Epidemiol, 2011. 64: p. 1283-93., https://www.ncbi.nlm.nih.gov/pubmed/21839614

6. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 8. Rating the quality of evidence--indirectness, J Clin Epidemiol, 2011. 64: p. 1303-10., https://www.ncbi.nlm.nih.gov/pubmed/21802903

7. Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., et.al. GRADE guidelines: 5. Rating the quality of evidence--publication bias, J Clin Epidemiol, 2011. 64: p. 1277-82., https://www.ncbi.nlm.nih.gov/pubmed/21802904

8. Armitage, J., Clinical Evaluation. In: Hodgkin Lymphoma - A Comprehensive Update On Diagnostics and Clinics (Engert A., ed.), Hodgkin Lymphoma, 2011. p. pp 65-76.

9. Fuchs, M., Hodgkin-Lymphome. Available from: https://www.onkopedia.com/de/onkopedia/guidelines/hodgkin-lymphom/@@view/html/index.html, 2016., https://www.onkopedia.com/de/onkopedia/guidelines/hodgkin-lymphom/@@view/html/index.html

10. Fuchs, R., Hodgkin Lymphom Klinik, Maligne Lymphome. Diagnostik & Therapie, 2007.

11. Mauch, P., Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults. Available from: http://cursoenarm.net/UPTODATE/contents/mobipreview.htm?26/6/26735?source=see_link, 2011.

12. Rosenwald, A., Pathology and Molecular Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma - A Comprehensive Update On Diagnostics and Clinics (Engert A., ed.), Hodgkin Lymphoma, 2011. p. 33 -48.

13. Adams, H. J., Kwee, T. C., de Keizer, B., Fijnheer, R., de Klerk, J. M., Littooij, A. S., et.al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?, Annals of Oncology, 2014. 25: p. 921-7., https://www.ncbi.nlm.nih.gov/pubmed/24351400

14. Adams, H. J., Nievelstein, R. A., Kwee, T. C., Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis, Br J Haematol, 2015c. 170: p. 356-66., https://www.ncbi.nlm.nih.gov/pubmed/25868485

15. V, o, l, t, i, n, et.al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18, 2018. 29 (9): p. 1926 - 1931.

16. Eichenauer, D. A., Engert, A., Andre, M., Federico, M., Illidge, T., Hutchings, M., et.al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2014. 25 Suppl 3: p. iii70-5., https://www.ncbi.nlm.nih.gov/pubmed/25185243

17. El-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bogsted, M., Bukh, A., et.al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma, J Clin Oncol, 2012. 30: p. 4508-14., https://www.ncbi.nlm.nih.gov/pubmed/23150698

18. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., et.al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting, J Clin Oncol, 1989. 7: p. 1630-6., https://www.ncbi.nlm.nih.gov/pubmed/2809679

19. Purz, S., Mauz-Korholz, C., Korholz, D., Hasenclever, D., Krausse, A., Sorge, I., et.al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma, J Clin Oncol, 2011. 29: p. 3523-8., https://www.ncbi.nlm.nih.gov/pubmed/21825262

20. Adams, H. J., Kwee, T. C., de Keizer, B., Fijnheer, R., de Klerk, J. M., Littooij, A. S., et.al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?, Annals of Oncology, 2014. 25: p. 921-7., https://www.ncbi.nlm.nih.gov/pubmed/24351400

21. Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Klasa, Richard, et.al. Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma, ASH Annual Meeting Abstracts, 2010. 116: p. 283-., http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/283

22. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., et.al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, 2006b. 107: p. 52-9., http://www.bloodjournal.org/content/bloodjournal/107/1/52.full.pdf

23. Bednaruk-Mlynski, E., Pienkowska, J., Skorzak, A., Malkowski, B., Kulikowski, W., Subocz, E., et.al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma, Leuk Lymphoma, 2015. 56: p. 377-82., http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.919635?needAccess=true

24. Girinsky, T., Auperin, A., Ribrag, V., Elleuch, M., Ferme, C., Bonniaud, G., et.al. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients, Int J Radiat Oncol Biol Phys, 2014. 89: p. 1047-52., https://www.sciencedirect.com/science/article/pii/S0360301614004970

25. Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., et.al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG), International Journal of Radiation Oncology, Biology, Physics, 2014. 89: p. 854-62., https://www.ncbi.nlm.nih.gov/pubmed/23790512

26. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Berthelsen, A. K., Keiding, S., et.al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma, Haematologica, 2006a. 91: p. 482-9., http://www.haematologica.org/content/haematol/91/4/482.full.pdf

27. Bednaruk-Mlynski, E., Pienkowska, J., Skorzak, A., Malkowski, B., Kulikowski, W., Subocz, E., et.al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma, Leuk Lymphoma, 2015. 56: p. 377-82., http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.919635?needAccess=true

28. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., et.al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial, Lancet (London, England), 2012. p. 1791-9., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/655/CN-00880655/frame.html, http://ac.els-cdn.com/S0140673611619405/1-s2.0-S0140673611619405-main.pdf?_tid=dc23364a-9507-11e6-ae67-00000aab0f6b&acdnat=1476777347_7bbee63f0430e63c4218a37237d2cfb6

29. Borchmann, P., Haverkamp, H., Lohri, A., Mey, U., Kreissl, S., Greil, R., et.al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group, Lancet Oncol, 2017. 18: p. 454-463., https://www.sciencedirect.com/science/article/pii/S1470204517301031

30. Kobe, C., Kuhnert, G., Kahraman, D., Haverkamp, H., Eich, H. T., Franke, M., et.al. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma, J Clin Oncol, 2014. 32: p. 1776-81., https://www.ncbi.nlm.nih.gov/pubmed/24799482

31. Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., et.al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG), International Journal of Radiation Oncology, Biology, Physics, 2014. 89: p. 854-62., https://www.ncbi.nlm.nih.gov/pubmed/23790512

32. Girinsky, T., Auperin, A., Ribrag, V., Elleuch, M., Ferme, C., Bonniaud, G., et.al. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients, Int J Radiat Oncol Biol Phys, 2014. 89: p. 1047-52., https://www.sciencedirect.com/science/article/pii/S0360301614004970

33. Weiler-Sagie, M., Kagna, O., Dann, E. J., Ben-Barak, A., Israel, O., Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT, Eur J Nucl Med Mol Imaging, 2014. 41: p. 1133-40., https://www.ncbi.nlm.nih.gov/pubmed/24570095

34. Chen-Liang, T. H., Martin-Santos, T., Jerez, A., Senent, L., Orero, M. T., Remigia, M. J., et.al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients, Am J Hematol, 2015. 90: p. 686-90., https://www.ncbi.nlm.nih.gov/pubmed/25925613

35. Adams, H. J., Nievelstein, R. A., Kwee, T. C., Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis, Br J Haematol, 2015c. 170: p. 356-66., https://www.ncbi.nlm.nih.gov/pubmed/25868485

36. Adams, H. J., Nievelstein, R. A., Kwee, T. C., Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma, Blood Rev, 2015b. 29: p. 417-25., https://www.sciencedirect.com/science/article/pii/S0268960X15000454

37. Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., et.al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 2014. 32: p. 3059-68., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083/pdf/zlj3059.pdf

38. Mehnert, Anja, Müller, Diana, Lehmann, Claudia, Koch, Uwe, Die deutsche Version des NCCN Distress-Thermometers, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 2006. 54: p. 213-223., http://econtent.hogrefe.com/doi/abs/10.1024/1661-4747.54.3.213, http://econtent.hogrefe.com/doi/pdf/10.1024/1661-4747.54.3.213

39. Herschbach, P., Book, K., Brandl, T., Keller, M., Marten-Mittag, B., The Basic Documentation for Psycho-Oncology (PO-Bado): an expert rating scale for the psychosocial experience of cancer patients, Onkologie, 2008. 31(11): p. 591-596., http://www.ncbi.nlm.nih.gov/pubmed/19145091

40. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF),, Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1, AWMF-Registernummer: 032/051OL, 2014., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/

41. Brillant, Corinne, Terschueren, Claudia, Gierer, Sylke, Franklin, Jeremy, Heidelbach, Stephanie, Paulus, Ursula, et.al. Differences in Survival Rates for Patients with Hodgkin Lymphoma, Who Were Treated Inside vs. Outside Therapy Optimisation Protocols in Germany, Blood, 2007. 110(11): p. 2321-2321.

42. Liu, Lifang, Giusti, Francesco, Schaapveld, Michael, Aleman, Berthe, Lugtenburg, Pieternella, Meijnders, Paul, et.al. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up, British Journal of Haematology, 2017. 176(1): p. 65-75., https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14379, https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14379

43. Blank, O., von Tresckow, B., Monsef, I., Specht, L., Engert, A., Skoetz, N., Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma, Cochrane Database Syst Rev, 2017. 4: p. Cd007110., https://www.ncbi.nlm.nih.gov/pubmed/28447341

44. Specht, L., Gray, R. G., Clarke, M. J., Peto, R., Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group, J Clin Oncol, 1998. 16: p. 830-43., https://www.ncbi.nlm.nih.gov/pubmed/9508163

45. Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., et.al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial, J Clin Oncol, 2007. 25: p. 3495-502., https://www.ncbi.nlm.nih.gov/pubmed/17606976

46. Noordijk, E. M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A. D., Kluin-Nelemans, J. C., et.al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials, J Clin Oncol, 2006. 24: p. 3128-35., https://www.ncbi.nlm.nih.gov/pubmed/16754934

47. Ferme, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., et.al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease, N Engl J Med, 2007. 357: p. 1916-27., http://www.nejm.org/doi/pdf/10.1056/NEJMoa064601

48. Blank, O., von Tresckow, B., Monsef, I., Specht, L., Engert, A., Skoetz, N., Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma, Cochrane Database Syst Rev, 2017. 4: p. Cd007110., https://www.ncbi.nlm.nih.gov/pubmed/28447341

49. Specht, L., Gray, R. G., Clarke, M. J., Peto, R., Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group, J Clin Oncol, 1998. 16: p. 830-43., https://www.ncbi.nlm.nih.gov/pubmed/9508163

50. Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., et.al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial, J Clin Oncol, 2007. 25: p. 3495-502., https://www.ncbi.nlm.nih.gov/pubmed/17606976

51. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., et.al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD, N Engl J Med, 1992. 327: p. 1478-84., http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102

52. Behringer, K., Goergen, H., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., et.al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial, Lancet (London, England), 2015. p. 1418-27., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/269/CN-01071269/frame.html, http://ac.els-cdn.com/S0140673614614690/1-s2.0-S0140673614614690-main.pdf?_tid=adc0e348-491f-11e7-ac8a-00000aacb35e&acdnat=1496578786_01c7ccf921527e5e5346aeb17f859e7d

53. Engert, A., Plutschow, A., Eich, H. T., Lohri, A., Dorken, B., Borchmann, P., et.al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma, N Engl J Med, 2010b. 363: p. 640-52., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000067

54. Sasse, S., Brockelmann, P. J., Goergen, H., Plutschow, A., Muller, H., Kreissl, S., et.al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials, Journal of Clinical Oncology, 2017. 35(18): p. 1999-2007., https://pubmed.ncbi.nlm.nih.gov/28418763/

55. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., et.al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD, N Engl J Med, 1992. 327: p. 1478-84., http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102

56. Engert, A., Plutschow, A., Eich, H. T., Lohri, A., Dorken, B., Borchmann, P., et.al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma, N Engl J Med, 2010b. 363: p. 640-52., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000067

57. Sasse, S., Brockelmann, P. J., Goergen, H., Plutschow, A., Muller, H., Kreissl, S., et.al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials, Journal of Clinical Oncology, 2017. 35(18): p. 1999-2007., https://pubmed.ncbi.nlm.nih.gov/28418763/

58. Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., et.al. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. p. 1936-42., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/780/CN-01085780/frame.html

59. Noordijk, E. M., Thomas, J., Fermé, C., van 't Veer, M. B., Brice, P., Diviné, M., et.al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL).Journal of Clinical Oncology, ASCO, 2005. 23: p. 6505.

60. Thomas, J., Ferme, C., Noordijk, E. M., Morschhauser, F., Girinsky, T., Gaillard, I., et.al. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial, International Journal of Radiation Oncology, Biology, Physics, 2018. 100(5): p. 1133-1145., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=29229324

61. Behringer, K., Goergen, H., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., et.al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial, Lancet (London, England), 2015. p. 1418-27., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/269/CN-01071269/frame.html, http://ac.els-cdn.com/S0140673614614690/1-s2.0-S0140673614614690-main.pdf?_tid=adc0e348-491f-11e7-ac8a-00000aacb35e&acdnat=1496578786_01c7ccf921527e5e5346aeb17f859e7d

62. Sickinger, Marie-Therese, von Tresckow, Bastian, Kobe, Carsten, Engert, Andreas, Borchmann, Peter, Skoetz, Nicole, Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma, Cochrane Database of Systematic Reviews, 2015., http://dx.doi.org/10.1002/14651858.CD010533.pub2

63. Thomas, J., Ferme, C., Noordijk, E. M., Morschhauser, F., Girinsky, T., Gaillard, I., et.al. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial, International Journal of Radiation Oncology, Biology, Physics, 2018. 100(5): p. 1133-1145., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=29229324

64. Olszewski, A. J., Shrestha, R., Castillo, J. J., Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base, J Clin Oncol, 2015. 33(6): p. 625-33., https://pubmed.ncbi.nlm.nih.gov/25584010/

65. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., et.al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma, New England Journal of Medicine, 2012. 366: p. 399-408., https://www.ncbi.nlm.nih.gov/pubmed/22149921

66. Hay, A. E., Klimm, B., Chen, B. E., Goergen, H., Shepherd, L. E., Fuchs, M., et.al. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma, Ann Oncol, 2013. 24(12): p. 3065-9., https://pubmed.ncbi.nlm.nih.gov/24121121/

67. Andre, M. P., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., et.al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial, J Clin Oncol, 2017. p. Jco2016686394., https://www.ncbi.nlm.nih.gov/pubmed/28291393

68. Fuchs, M., Goergen, H., Kobe, C., Kuhnert, G., Lohri, A., Greil, R., et.al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group, J Clin Oncol, 2019. p. Jco1900964., https://pubmed.ncbi.nlm.nih.gov/31498753/

69. Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et.al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma, The New England journal of medicine, 2015. p. 1598-607., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/988/CN-01066988/frame.html

70. Sickinger, Marie-Therese, von Tresckow, Bastian, Kobe, Carsten, Engert, Andreas, Borchmann, Peter, Skoetz, Nicole, Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma, Cochrane Database of Systematic Reviews, 2015., http://dx.doi.org/10.1002/14651858.CD010533.pub2

71. Girinsky, T., Pichenot, C., Beaudre, A., Ghalibafian, M., Lefkopoulos, D., Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?, International Journal of Radiation Oncology, Biology, Physics, 2006. 64: p. 218-26., https://www.ncbi.nlm.nih.gov/pubmed/16169675

72. Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., et.al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group, J Clin Oncol, 2003. 21: p. 3601-8., https://www.ncbi.nlm.nih.gov/pubmed/12913100

73. Sasse, S., Klimm, B., Görgen, H., Fuchs, M., Heyden-Honerkamp, A., Lohri, A., et.al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma, Annals of Oncology, 2012. 23(11): p. 2953-2959., http://dx.doi.org/10.1093/annonc/mds110

74. Hoskin, P. J., Smith, P., Maughan, T. S., Gilson, D., Vernon, C., Syndikus, I., et.al. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma, Clin Oncol (R Coll Radiol), 2005. 17: p. 47-53., https://www.sciencedirect.com/science/article/abs/pii/S0936655504002596

75. Girinsky, T., Pichenot, C., Beaudre, A., Ghalibafian, M., Lefkopoulos, D., Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?, International Journal of Radiation Oncology, Biology, Physics, 2006. 64: p. 218-26., https://www.ncbi.nlm.nih.gov/pubmed/16169675

76. Antoni, D., Natarajan-Ame, S., Meyer, P., Niederst, C., Bourahla, K., Noel, G., Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease, Radiat Oncol, 2013. 8: p. 112., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671200/pdf/1748-717X-8-112.pdf

77. Cella, L., Liuzzi, R., Magliulo, M., Conson, M., Camera, L., Salvatore, M., et.al. Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques, Radiat Oncol, 2010. 5: p. 33., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881006/pdf/1748-717X-5-33.pdf

78. Cella, L., Conson, M., Pressello, M. C., Molinelli, S., Schneider, U., Donato, V., et.al. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms, Radiat Oncol, 2013. 8: p. 22., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641014/pdf/1748-717X-8-22.pdf, https://air.unimi.it/retrieve/handle/2434/224937/287681/1748-717X-8-22.pdf

79. Filippi, A. R., Ragona, R., Piva, C., Scafa, D., Fiandra, C., Fusella, M., et.al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk, Int J Radiat Oncol Biol Phys, 2015. 92: p. 161-8., https://www.ncbi.nlm.nih.gov/pubmed/25863763

80. Maraldo, M. V., Brodin, N. P., Aznar, M. C., Vogelius, I. R., Munck af Rosenschold, P., Petersen, P. M., et.al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma, Ann Oncol, 2013. 24: p. 2113-8., https://www.ncbi.nlm.nih.gov/pubmed/23619032

81. Koeck, J., Abo-Madyan, Y., Eich, H. T., Stieler, F., Fleckenstein, J., Kriz, J., et.al. Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease, Strahlenther Onkol, 2012. 188: p. 653-9., https://www.springermedizin.de/clinical-relevance-of-different-dose-calculation-strategies-for-/7992990

82. Baues, C., Marnitz, S., Engert, A., Baus, W., Jablonska, K., Fogliata, A., et.al. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY, Radiation Oncology, 2018. 13(1): p. 122., https://ro-journal.biomedcentral.com/track/pdf/10.1186/s13014-018-1066-2

83. Edvardsson, A., Kugele, M., Alkner, S., Enmark, M., Nilsson, J., Kristensen, I., et.al. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy, Acta Oncologica, 2019. 58(1): p. 95-104., https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2018.1512153?needAccess=true

84. Voong, K. R., McSpadden, K., Pinnix, C. C., Shihadeh, F., Reed, V., Salehpour, M. R., et.al. Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma, Radiat Oncol, 2014. 9: p. 94., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013438/pdf/1748-717X-9-94.pdf

85. Zeng, C., Plastaras, J. P., James, P., Tochner, Z. A., Hill-Kayser, C. E., Hahn, S. M., et.al. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment, Acta Oncologica, 2016. 55(9-10): p. 1132-1138., https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2016.1191665?needAccess=true

86. Edvardsson, A., Kugele, M., Alkner, S., Enmark, M., Nilsson, J., Kristensen, I., et.al. Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy, Acta Oncologica, 2019. 58(1): p. 95-104., https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2018.1512153?needAccess=true

87. Antoni, D., Natarajan-Ame, S., Meyer, P., Niederst, C., Bourahla, K., Noel, G., Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease, Radiat Oncol, 2013. 8: p. 112., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671200/pdf/1748-717X-8-112.pdf

88. Cella, L., Liuzzi, R., Magliulo, M., Conson, M., Camera, L., Salvatore, M., et.al. Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques, Radiat Oncol, 2010. 5: p. 33., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881006/pdf/1748-717X-5-33.pdf

89. Filippi, A. R., Ragona, R., Piva, C., Scafa, D., Fiandra, C., Fusella, M., et.al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk, Int J Radiat Oncol Biol Phys, 2015. 92: p. 161-8., https://www.ncbi.nlm.nih.gov/pubmed/25863763

90. Voong, K. R., McSpadden, K., Pinnix, C. C., Shihadeh, F., Reed, V., Salehpour, M. R., et.al. Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma, Radiat Oncol, 2014. 9: p. 94., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013438/pdf/1748-717X-9-94.pdf

91. Cella, L., Conson, M., Pressello, M. C., Molinelli, S., Schneider, U., Donato, V., et.al. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms, Radiat Oncol, 2013. 8: p. 22., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641014/pdf/1748-717X-8-22.pdf, https://air.unimi.it/retrieve/handle/2434/224937/287681/1748-717X-8-22.pdf

92. Maraldo, M. V., Brodin, N. P., Aznar, M. C., Vogelius, I. R., Munck af Rosenschold, P., Petersen, P. M., et.al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma, Ann Oncol, 2013. 24: p. 2113-8., https://www.ncbi.nlm.nih.gov/pubmed/23619032

93. Weber, D. C., Johanson, S., Peguret, N., Cozzi, L., Olsen, D. R., Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients, International Journal of Radiation Oncology, Biology, Physics, 2011. 81: p. 490-7., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=20800383

94. De Sanctis, V., Bolzan, C., D'Arienzo, M., Bracci, S., Fanelli, A., Cox, M. C., et.al. Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?, Radiat Oncol, 2012. 7: p. 129., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484070/pdf/1748-717X-7-129.pdf

95. Schneider, U., Sumila, M., Robotka, J., Weber, D., Gruber, G., Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study, Radiat Oncol, 2014. 9: p. 58., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942771/pdf/1748-717X-9-58.pdf

96. Lu, N. N., Li, Y. X., Wu, R. Y., Zhang, X. M., Wang, W. H., Jin, J., et.al. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement, International Journal of Radiation Oncology, Biology, Physics, 2012. 84: p. 210-6., https://www.ncbi.nlm.nih.gov/pubmed/22436783

97. Parikh, R. R., Grossbard, M. L., Harrison, L. B., Yahalom, J., Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma, Radiother Oncol, 2016. 118: p. 52-9., https://www.ncbi.nlm.nih.gov/pubmed/26522061

98. Fiandra, C., Filippi, A. R., Catuzzo, P., Botticella, A., Ciammella, P., Franco, P., et.al. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations, Radiat Oncol, 2012. 7: p. 186., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502518/pdf/1748-717X-7-186.pdf

99. Koeck, J., Abo-Madyan, Y., Eich, H. T., Stieler, F., Fleckenstein, J., Kriz, J., et.al. Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease, Strahlenther Onkol, 2012. 188: p. 653-9., https://www.springermedizin.de/clinical-relevance-of-different-dose-calculation-strategies-for-/7992990

100. Paumier, A., Khodari, W., Beaudre, A., Ghalibafian, M., Blanchard, P., Al Hamokles, H., et.al. [Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: experience of the Gustave-Roussy Institute], Cancer Radiotherapie, 2011. 15: p. 709-15., https://www.ncbi.nlm.nih.gov/m/pubmed/22116023/

101. Kriz, J., Spickermann, M., Lehrich, P., Schmidberger, H., Reinartz, G., Eich, H., et.al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT, Strahlentherapie und Onkologie, 2015. 191: p. 717-25., https://www.ncbi.nlm.nih.gov/pubmed/25876905

102. Rechner, L. A., Maraldo, M. V., Vogelius, I. R., Zhu, X. R., Dabaja, B. S., Brodin, N. P., et.al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold, Radiotherapy & Oncology, 2017. 125(1): p. 41-47., https://www.sciencedirect.com/science/article/pii/S0167814017325094?via%3Dihub

103. Kriz, J., Spickermann, M., Lehrich, P., Schmidberger, H., Reinartz, G., Eich, H., et.al. Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT, Strahlentherapie und Onkologie, 2015. 191: p. 717-25., https://www.ncbi.nlm.nih.gov/pubmed/25876905

104. Paumier, A., Ghalibafian, M., Gilmore, J., Beaudre, A., Blanchard, P., el Nemr, M., et.al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma, International Journal of Radiation Oncology, Biology, Physics, 2012. 82: p. 1522-7., https://www.ncbi.nlm.nih.gov/pubmed/21705151

105. Baues, C., Marnitz, S., Engert, A., Baus, W., Jablonska, K., Fogliata, A., et.al. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY, Radiation Oncology, 2018. 13(1): p. 122., https://ro-journal.biomedcentral.com/track/pdf/10.1186/s13014-018-1066-2

106. Paumier, A., Khodari, W., Beaudre, A., Ghalibafian, M., Blanchard, P., Al Hamokles, H., et.al. [Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: experience of the Gustave-Roussy Institute], Cancer Radiotherapie, 2011. 15: p. 709-15., https://www.ncbi.nlm.nih.gov/m/pubmed/22116023/

107. Chera, B. S., Rodriguez, C., Morris, C. G., Louis, D., Yeung, D., Li, Z., et.al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy, International Journal of Radiation Oncology, Biology, Physics, 2009. 75: p. 1173-80., https://www.ncbi.nlm.nih.gov/pubmed/19386423

108. Hoppe, B. S., Flampouri, S., Su, Z., Morris, C. G., Latif, N., Dang, N. H., et.al. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study, International Journal of Radiation Oncology, Biology, Physics, 2012. 83: p. 260-7., https://www.ncbi.nlm.nih.gov/pubmed/22014950

109. Sachsman, S., Hoppe, B. S., Mendenhall, N. P., Holtzman, A., Li, Z., Slayton, W., et.al. Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma, Leukemia & Lymphoma, 2015. 56: p. 2019-24., http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.975802?needAccess=true

110. Toltz, A., Shin, N., Mitrou, E., Laude, C., Freeman, C. R., Seuntjens, J., et.al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential, Journal of Applied Clinical Medical Physics, 2015. 16: p. 5386., https://www.ncbi.nlm.nih.gov/pubmed/26699298

111. Horn, S., Fournier-Bidoz, N., Pernin, V., Peurien, D., Vaillant, M., Dendale, R., et.al. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy, Cancer Radiotherapie, 2016. 20: p. 98-103., https://www.ncbi.nlm.nih.gov/pubmed/26992750

112. Eley, J. G., Friedrich, T., Homann, K. L., Howell, R. M., Scholz, M., Durante, M., et.al. Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy, International Journal of Radiation Oncology, Biology, Physics, 2016. 95(1): p. 279-86., https://www.sciencedirect.com/science/article/pii/S0360301616001528?via%3Dihub

113. Hoppe, B. S., Hill-Kayser, C. E., Tseng, Y. D., Flampouri, S., Elmongy, H. M., Cahlon, O., et.al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma, Annals of Oncology, 2017. 28(9): p. 2179-2184., https://pubmed.ncbi.nlm.nih.gov/28911093/

114. Hoppe, B. S., Tsai, H., Larson, G., Laramore, G. E., Vargas, C., Tseng, Y. D., et.al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry, Acta Oncologica, 2016. 55(11): p. 1378-1380., https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2016.1197422?needAccess=true

115. Ntentas, G., Dedeckova, K., Andrlik, M., Aznar, M. C., George, B., Kubes, J., et.al. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?, Practical Radiation Oncology, 2019. 9(3): p. 179-187., https://www.sciencedirect.com/science/article/pii/S1879850019300074?via%3Dihub

116. Zeng, C., Plastaras, J. P., James, P., Tochner, Z. A., Hill-Kayser, C. E., Hahn, S. M., et.al. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment, Acta Oncologica, 2016. 55(9-10): p. 1132-1138., https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2016.1191665?needAccess=true

117. Rechner, L. A., Maraldo, M. V., Vogelius, I. R., Zhu, X. R., Dabaja, B. S., Brodin, N. P., et.al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold, Radiotherapy & Oncology, 2017. 125(1): p. 41-47., https://www.sciencedirect.com/science/article/pii/S0167814017325094?via%3Dihub

118. Hoppe, B. S., Hill-Kayser, C. E., Tseng, Y. D., Flampouri, S., Elmongy, H. M., Cahlon, O., et.al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma, Annals of Oncology, 2017. 28(9): p. 2179-2184., https://pubmed.ncbi.nlm.nih.gov/28911093/

119. Hoppe, B. S., Tsai, H., Larson, G., Laramore, G. E., Vargas, C., Tseng, Y. D., et.al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry, Acta Oncologica, 2016. 55(11): p. 1378-1380., https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2016.1197422?needAccess=true

120. Ntentas, G., Dedeckova, K., Andrlik, M., Aznar, M. C., George, B., Kubes, J., et.al. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?, Practical Radiation Oncology, 2019. 9(3): p. 179-187., https://www.sciencedirect.com/science/article/pii/S1879850019300074?via%3Dihub

121. Chera, B. S., Rodriguez, C., Morris, C. G., Louis, D., Yeung, D., Li, Z., et.al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy, International Journal of Radiation Oncology, Biology, Physics, 2009. 75: p. 1173-80., https://www.ncbi.nlm.nih.gov/pubmed/19386423

122. Hoppe, B. S., Flampouri, S., Su, Z., Morris, C. G., Latif, N., Dang, N. H., et.al. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study, International Journal of Radiation Oncology, Biology, Physics, 2012. 83: p. 260-7., https://www.ncbi.nlm.nih.gov/pubmed/22014950

123. Sachsman, S., Hoppe, B. S., Mendenhall, N. P., Holtzman, A., Li, Z., Slayton, W., et.al. Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma, Leukemia & Lymphoma, 2015. 56: p. 2019-24., http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.975802?needAccess=true

124. Toltz, A., Shin, N., Mitrou, E., Laude, C., Freeman, C. R., Seuntjens, J., et.al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential, Journal of Applied Clinical Medical Physics, 2015. 16: p. 5386., https://www.ncbi.nlm.nih.gov/pubmed/26699298

125. Horn, S., Fournier-Bidoz, N., Pernin, V., Peurien, D., Vaillant, M., Dendale, R., et.al. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy, Cancer Radiotherapie, 2016. 20: p. 98-103., https://www.ncbi.nlm.nih.gov/pubmed/26992750

126. Eley, J. G., Friedrich, T., Homann, K. L., Howell, R. M., Scholz, M., Durante, M., et.al. Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy, International Journal of Radiation Oncology, Biology, Physics, 2016. 95(1): p. 279-86., https://www.sciencedirect.com/science/article/pii/S0360301616001528?via%3Dihub

127. Andre, M. P., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., et.al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial, J Clin Oncol, 2017. p. Jco2016686394., https://www.ncbi.nlm.nih.gov/pubmed/28291393

128. Barrington, S. F., Phillips, E. H., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et.al. Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study, J Clin Oncol, 2019. 37(20): p. 1732-1741., https://ascopubs.org/doi/full/10.1200/JCO.18.01799?journalCode=jco

129. Fuchs, M., Goergen, H., Kobe, C., Kuhnert, G., Lohri, A., Greil, R., et.al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group, J Clin Oncol, 2019. p. Jco1900964., https://pubmed.ncbi.nlm.nih.gov/31498753/

130. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., et.al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, 2006b. 107: p. 52-9., http://www.bloodjournal.org/content/bloodjournal/107/1/52.full.pdf

131. Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T., Timothy, A. R., Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma, Ann Oncol, 2005. 16: p. 1160-8., https://www.ncbi.nlm.nih.gov/pubmed/15939713

132. Aldin, A, Umlauff, L, Estcourt, LJ, Collins, G, Moons, KG, Engert, A, et.al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies., Cochrane Database Syst Rev, 2019. 9 (): p. CD012643., https://pubmed.ncbi.nlm.nih.gov/31525824/

133. Aldin, A, Umlauff, L, Estcourt, LJ, Collins, G, Moons, KG, Engert, A, et.al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies., Cochrane Database Syst Rev, 2020. 1 (): p. CD012643., https://pubmed.ncbi.nlm.nih.gov/31930780/

134. de Wit, M., Bohuslavizki, K. H., Buchert, R., Bumann, D., Clausen, M., Hossfeld, D. K., 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma, Ann Oncol, 2001. 12: p. 29-37., https://www.ncbi.nlm.nih.gov/pubmed/11249046

135. Weihrauch, M. R., Re, D., Scheidhauer, K., Ansen, S., Dietlein, M., Bischoff, S., et.al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease, Blood, 2001. 98: p. 2930-4., https://www.ncbi.nlm.nih.gov/pubmed/11698273

136. Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P., Balzarini, J., et.al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?, Br J Haematol, 2001. 115: p. 272-8., https://www.ncbi.nlm.nih.gov/pubmed/11703321

137. Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J., Kittner, T., et.al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma, Br J Haematol, 2001. 115: p. 793-800., https://www.ncbi.nlm.nih.gov/pubmed/11843811

138. Sher, D. J., Mauch, P. M., Van Den Abbeele, A., LaCasce, A. S., Czerminski, J., Ng, A. K., Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy, Ann Oncol, 2009. 20: p. 1848-53., https://www.ncbi.nlm.nih.gov/pubmed/19541793

139. Barrington, S. F., Phillips, E. H., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et.al. Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study, J Clin Oncol, 2019. 37(20): p. 1732-1741., https://ascopubs.org/doi/full/10.1200/JCO.18.01799?journalCode=jco

140. Andre, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., et.al. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial, J Clin Oncol, 2017. 35: p. 1786-1794., https://www.ncbi.nlm.nih.gov/pubmed/28291393

141. Raemaekers, J. M., Andre, M. P., Federico, M., Girinsky, T., Oumedaly, R., Brusamolino, E., et.al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial, Journal of Clinical Oncology, 2014. 32: p. 1188-94., https://www.ncbi.nlm.nih.gov/pubmed/24637998

142. Schaapveld, M., Aleman, B. M., van Eggermond, A. M., Janus, C. P., Krol, A. D., van der Maazen, R. W., et.al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma, N Engl J Med, 2015. 373: p. 2499-511., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1505949

143. Veit-Rubin, N., Rapiti, E., Usel, M., Benhamou, S., Vinh-Hung, V., Vlastos, G., et.al. Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphoma, Oncologist, 2012. 17: p. 783-91., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380877/pdf/onc783.pdf

144. Borchmann, Peter, POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG, EHA Library, 2020.

145. Eich, H. T., Diehl, V., Gorgen, H., Pabst, T., Markova, J., Debus, J., et.al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial, J Clin Oncol, 2010. 28: p. 4199-206., https://www.ncbi.nlm.nih.gov/pubmed/20713848

146. von Tresckow, Bastian, Kreissl, Stefanie, Goergen, Helen, Diehl, Volker, Engert, Andreas, Borchmann, Peter, eBEACOPP followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin lymphoma: long- term follow-up of the German Hodgkin Study Group HD9 and HD12 trials, & Kreissl not published.

147. Sasse, S., Brockelmann, P. J., Goergen, H., Plutschow, A., Muller, H., Kreissl, S., et.al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials, J Clin Oncol, 2017. p. Jco2016709410., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131364/

148. Borchmann, Peter, POSITRON EMISSION TOMOGRAPHY GUIDED OMISSION OF RADIOTHERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE III HD17 TRIAL BY THE GHSG, EHA Library, 2020.

149. Skoetz, N., Will, A., Monsef, I., Brillant, C., Engert, A., von Tresckow, B., Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma, Cochrane Database Syst Rev, 2017. 5: p. Cd007941., https://www.ncbi.nlm.nih.gov/pubmed/28541603

150. Eich, H. T., Diehl, V., Gorgen, H., Pabst, T., Markova, J., Debus, J., et.al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial, J Clin Oncol, 2010. 28: p. 4199-206., https://www.ncbi.nlm.nih.gov/pubmed/20713848

151. von Tresckow, B., Plutschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., et.al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial, Journal of Clinical Oncology, 2012. 30: p. 907-13., https://www.ncbi.nlm.nih.gov/pubmed/20713848

152. Ferme, Christophe, Divine, Marine, Vranovsky, Andrej, Morschhauser, Frank, Bouabdallah, Reda, Gabarre, Jean, et.al. Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial, ASH Annual Meeting Abstracts, 2005. 106: p. 813-., http://www.bloodjournal.org/content/106/11/813

153. Arakelyan, N., Jais, J. P., Tomowiack, C., Colombat, P., Berthou, C., Desablens, B., et.al. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation, Leukemia & lymphoma, 2013. p. 76-82., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/800/CN-00867800/frame.html, http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.701737?needAccess=true

154. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., et.al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease, N Engl J Med, 2003. 348: p. 2386-95., http://www.nejm.org/doi/pdf/10.1056/NEJMoa022473

155. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W. D., et.al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study, J Clin Oncol, 2009. 27: p. 4548-54., http://jco.ascopubs.org/content/27/27/4548.full.pdf

156. Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., et.al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial, J Clin Oncol, 2009. 27: p. 805-11., http://jco.ascopubs.org/content/27/5/805.full.pdf

157. Gillessen, Sarah, Plütschow, Annette, Fuchs, Michael, Markova, Jana, Greil, Richard, Topp, Max S., et.al. Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial, Blood, 2019. 134(Supplement_1): p. 129 - 129., https://doi.org/10.1182/blood-2019-125249

158. Skoetz, N., Will, A., Monsef, I., Brillant, C., Engert, A., von Tresckow, B., Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma, Cochrane Database Syst Rev, 2017. 5: p. Cd007941., https://www.ncbi.nlm.nih.gov/pubmed/28541603

159. Ballova, V., Ruffer, J. U., Haverkamp, H., Pfistner, B., Muller-Hermelink, H. K., Duhmke, E., et.al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly), Ann Oncol, 2005. 16: p. 124-31., http://annonc.oxfordjournals.org/content/16/1/124.full.pdf

160. Wongso, D., Fuchs, M., Plutschow, A., Klimm, B., Sasse, S., Hertenstein, B., et.al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group, J Clin Oncol, 2013. 31: p. 2819-24., https://www.ncbi.nlm.nih.gov/pubmed/23796987

161. Boll, B., Goergen, H., Behringer, K., Brockelmann, P. J., Hitz, F., Kerkhoff, A., et.al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials, Blood, 2016. 127: p. 2189-92., http://www.bloodjournal.org/content/bloodjournal/127/18/2189.full.pdf

162. Canellos, G. P., Abramson, J. S., Fisher, D. C., LaCasce, A. S., Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy, J Clin Oncol, 2010. 28: p. 1611-5., http://jco.ascopubs.org/content/28/9/1611.full.pdf

163. Herbst, C., Rehan, F. A., Skoetz, N., Bohlius, J., Brillant, C., Schulz, H., et.al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma, Cochrane Database Syst Rev, 2011. p. CD007110., https://www.ncbi.nlm.nih.gov/pubmed/21328291

164. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A., Wells, W. A., et.al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group, J Clin Oncol, 2005. 23: p. 4634-42., http://jco.ascopubs.org/content/23/21/4634.full.pdf

165. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., et.al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma, N Engl J Med, 2011., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1111961

166. Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., et.al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma, Blood, 2008. 112: p. 3989-94., http://www.bloodjournal.org/content/bloodjournal/112/10/3989.full.pdf

167. Adams, H. J., Nievelstein, R. A., Kwee, T. C., Outcome of Hodgkin Lymphoma Patients With a Posttreatment (18)F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis, Pediatr Hematol Oncol, 2015d. 32: p. 515-24., http://www.tandfonline.com/doi/pdf/10.3109/08880018.2015.1085934

168. Adams, H. J., Nievelstein, R. A., Kwee, T. C., Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy, Ann Hematol, 2015a., https://www.ncbi.nlm.nih.gov/pubmed/26482577

169. Schellong, G., Potter, R., Bramswig, J., Wagner, W., Prott, F. J., Dorffel, W., et.al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group, J Clin Oncol, 1999. 17: p. 3736-44., http://jco.ascopubs.org/content/17/12/3736.full.pdf

170. Sasse, S., Brockelmann, P. J., Goergen, H., Plutschow, A., Muller, H., Kreissl, S., et.al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials, J Clin Oncol, 2017. p. Jco2016709410., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131364/

171. Hasenclever, D., Brosteanu, O., Gerike, T., Loeffler, M., Modelling of chemotherapy: the effective dose approach, Ann Hematol, 2001. 80 Suppl 3: p. B89-94., https://www.ncbi.nlm.nih.gov/pubmed/11757718

172. Engert, A., Eichenauer, D. A., Dreyling, M., Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2010c. 21 Suppl 5: p. v168-71., http://www.ncbi.nlm.nih.gov/pubmed/20555072

173. Behringer, K., Goergen, H., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., et.al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial, Lancet, 2015. 385: p. 1418-27., https://www.ncbi.nlm.nih.gov/pubmed/25539730

174. Wirth, A., Mikhaeel, N. G., Aleman, B. M. P., Pinnix, C. C., Constine, L. S., Ricardi, U., et.al. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines, Int J Radiat Oncol Biol Phys, 2020. 107(5): p. 909-933., https://pubmed.ncbi.nlm.nih.gov/32272184/

175. Skoetz, N., Trelle, S., Rancea, M., Haverkamp, H., Diehl, V., Engert, A., et.al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis, Lancet Oncology, 2013. 14: p. 943-52., https://www.ncbi.nlm.nih.gov/pubmed/23948348

176. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., et.al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial, Lancet (London, England), 2012. p. 1791-9., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/655/CN-00880655/frame.html, http://ac.els-cdn.com/S0140673611619405/1-s2.0-S0140673611619405-main.pdf?_tid=dc23364a-9507-11e6-ae67-00000aab0f6b&acdnat=1476777347_7bbee63f0430e63c4218a37237d2cfb6

177. Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., et.al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Lancet, 2018. 390(10114): p. 2790-2802., https://pubmed.ncbi.nlm.nih.gov/29061295/

178. Engert, Andreas, Goergen, Helen, Markova, Jana, Pabst, Thomas, Meissner, Julia, Zijlstra, Josée M., et.al. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group, HemaSphere, 2017. 1(1): p. e5-e5., https://pubmed.ncbi.nlm.nih.gov/31723734, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745969/

179. von Tresckow, B., Kreissl, S., Goergen, H., Bröckelmann, P. J., Pabst, T., Fridrik, M., et.al. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials, Lancet Haematol, 2018. 5(10): p. e462-e473., https://pubmed.ncbi.nlm.nih.gov/30290903/

180. Engert, Andreas, Goergen, Helen, Markova, Jana, Pabst, Thomas, Meissner, Julia, Zijlstra, Josée M., et.al. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group, HemaSphere, 2017. 1(1): p. e5-e5., https://pubmed.ncbi.nlm.nih.gov/31723734, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745969/

181. Johnson, P., Federico, M., Kirkwood, A., Fossa, A., Berkahn, L., Carella, A., et.al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma, N Engl J Med, 2016. 374: p. 2419-29., http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510093

182. Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., et.al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496), Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. p. 684-91., http://jco.ascopubs.org/content/31/6/684.full.pdf

183. Hoskin, P. J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B. W., et.al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244, J Clin Oncol, 2009. 27: p. 5390-6., https://www.ncbi.nlm.nih.gov/pubmed/19738111

184. Viviani , Simonetta, Zinzani , Pier Luigi, Rambaldi , Alessandro, Brusamolino , Ercole, Levis , Alessandro, Bonfante , Valeria, et.al. ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned, New England Journal of Medicine, 2011. 365: p. 203-212., http://www.nejm.org/doi/full/10.1056/NEJMoa1100340, http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100340

185. Meignan, M., Gallamini, A., Meignan, M., Gallamini, A., Haioun, C., Report on the First International Workshop on Interim-PET-Scan in Lymphoma, Leuk Lymphoma, 2009. 50(8): p. 1257-60.

186. Kobe, C., Goergen, H., Baues, C., Kuhnert, G., Voltin, C. A., Zijlstra, J., et.al. Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma, Blood, 2018. 132(21): p. 2273-2279., https://www.tandfonline.com/doi/full/10.1080/10428190903040048

187. Carde, P., Karrasch, M., Fortpied, C., Brice, P., Khaled, H., Casasnovas, O., et.al. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score >/= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial, J Clin Oncol, 2016. 34: p. 2028-36., https://www.ncbi.nlm.nih.gov/pubmed/27114593

188. Mounier, N., Brice, P., Bologna, S., Briere, J., Gaillard, I., Voillat, L., et.al. ABVD (eight cycles) versus beacopp (4 escalated cycles to 4 baseline) in stages III-IV low risk hodgkin lymphoma (IPS 0-2): Final results of LYSA H34 trial, Hematological oncology, 2013. p. 138-9., https://www.ncbi.nlm.nih.gov/pubmed/24827123

189. Andre, M., Fortpied, C, Viviani, S., Bellei, M., Carde, P., Hutchings, M., et.al. Overall survival impact of BEACOPP versus ABVD in advanced hodgkin lymphoma: a pooled analysis of 4 randomized trials, 10th International Symposium on Hodgkin Lymphoma, 2016. 101: p. 19 (T002)., https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01502859

190. Skoetz, N., Trelle, S., Rancea, M., Haverkamp, H., Diehl, V., Engert, A., et.al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis, Lancet Oncology, 2013. 14: p. 943-52., https://www.ncbi.nlm.nih.gov/pubmed/23948348

191. von Tresckow, B., Kreissl, S., Goergen, H., Bröckelmann, P. J., Pabst, T., Fridrik, M., et.al. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials, Lancet Haematol, 2018. 5(10): p. e462-e473., https://pubmed.ncbi.nlm.nih.gov/30290903/

192. Borchmann, P., Haverkamp, H., Diehl, V., Cerny, T., Markova, J., Ho, A. D., et.al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group, J Clin Oncol, 2011. 29: p. 4234-42., https://www.ncbi.nlm.nih.gov/pubmed/21990399

193. Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., et.al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Lancet, 2018. 390(10114): p. 2790-2802., https://pubmed.ncbi.nlm.nih.gov/29061295/

194. Younes , Anas, Bartlett , Nancy L., Leonard , John P., Kennedy , Dana A., Lynch , Carmel M., Sievers , Eric L., et.al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas, New England Journal of Medicine, 2010. 363: p. 1812-1821., http://www.nejm.org/doi/full/10.1056/NEJMoa1002965, http://www.nejm.org/doi/pdf/10.1056/NEJMoa1002965

195. Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., et.al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate, Clin Cancer Res, 2010. 16: p. 888-97., http://clincancerres.aacrjournals.org/content/clincanres/16/3/888.full.pdf

196. Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., et.al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 2012. 30: p. 2183-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646316/pdf/zlj2183.pdf

197. Younes, A., Connors, J. M., Park, S. I., Fanale, M., O'Meara, M. M., Hunder, N. N., et.al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study, Lancet Oncol, 2013. 14: p. 1348-56., https://www.ncbi.nlm.nih.gov/pubmed/24239220

198. Connors, JM, Jurczak, W, Straus, DJ, Ansell, SM, Kim, WS, Gallamini, A, et.al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma., N Engl J Med, 2018. 378 (4)(4): p. 331-344., https://pubmed.ncbi.nlm.nih.gov/29224502/

199. Eichenauer, Dennis A., Plütschow, Annette, Kreissl, Stefanie, Sökler, Martin, Hellmuth, Johannes C., Meissner, Julia, et.al. Randomized phase II study of targeted BEACOPP variants incorporating Brentuximab vedotin in the first-line treatment of advanced classical Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG), 2017 accepted, not published.

200. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., et.al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial, Lancet, 2012. 379: p. 1791-9., https://www.sciencedirect.com/science/article/pii/S0140673611619405

201. Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., et.al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma, Blood, 2008. 112: p. 3989-94., http://www.bloodjournal.org/content/bloodjournal/112/10/3989.full.pdf

202. Borchmann, P., Haverkamp, H., Diehl, V., Cerny, T., Markova, J., Ho, A. D., et.al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group, J Clin Oncol, 2011. 29: p. 4234-42., https://www.ncbi.nlm.nih.gov/pubmed/21990399

203. Vijayakumar, S., Myrianthopoulos, L. C., An updated dose-response analysis in Hodgkin's disease, Radiother Oncol, 1992. 24: p. 1-13., https://www.ncbi.nlm.nih.gov/pubmed/1620882

204. Brincker, H., Bentzen, S. M., A re-analysis of available dose-response and time-dose data in Hodgkin's disease, Radiother Oncol, 1994. 30: p. 227-30., https://www.ncbi.nlm.nih.gov/pubmed/8209006

205. Aleman, B. M., Raemaekers, J. M., Tomisic, R., Baaijens, M. H., Bortolus, R., Lybeert, M. L., et.al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma, Int J Radiat Oncol Biol Phys, 2007. 67: p. 19-30., https://www.ncbi.nlm.nih.gov/pubmed/17097834

206. Loeffler, M., Brosteanu, O., Hasenclever, D., Sextro, M., Assouline, D., Bartolucci, A. A., et.al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group, J Clin Oncol, 1998. 16: p. 818-29., https://www.ncbi.nlm.nih.gov/pubmed/9508162

207. Aleman, B. M., Raemaekers, J. M., Tirelli, U., Bortolus, R., van 't Veer, M. B., Lybeert, M. L., et.al. Involved-field radiotherapy for advanced Hodgkin's lymphoma, N Engl J Med, 2003. 348: p. 2396-406., http://www.nejm.org/doi/pdf/10.1056/NEJMoa022628

208. Vijayakumar, S., Myrianthopoulos, L. C., An updated dose-response analysis in Hodgkin's disease, Radiother Oncol, 1992. 24: p. 1-13., https://www.ncbi.nlm.nih.gov/pubmed/1620882

209. Brincker, H., Bentzen, S. M., A re-analysis of available dose-response and time-dose data in Hodgkin's disease, Radiother Oncol, 1994. 30: p. 227-30., https://www.ncbi.nlm.nih.gov/pubmed/8209006

210. Proctor, S. J., White, J., Jones, G. L., An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme, Eur J Haematol Suppl, 2005. p. 63-7., https://www.ncbi.nlm.nih.gov/pubmed/16007871

211. Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., et.al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group, J Clin Oncol, 2005. 23: p. 5052-60., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906856/

212. Diepstra, A., van Imhoff, G. W., Schaapveld, M., Karim-Kos, H., van den Berg, A., Vellenga, E., et.al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients, J Clin Oncol, 2009. 27: p. 3815-21., https://www.ncbi.nlm.nih.gov/pubmed/19470931

213. Gervais-Fagnou, D. D., Girouard, C., Laperriere, N., Pintillie, M., Goss, P. E., Breast cancer in women following supradiaphragmatic irradiation for Hodgkin's disease, Oncology, 1999. 57: p. 224-31., http://www.ncbi.nlm.nih.gov/pubmed/10545791

214. Boll, B., Bredenfeld, H., Gorgen, H., Halbsguth, T., Eich, H. T., Soekler, M., et.al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma, Blood, 2011. 118: p. 6292-8., https://www.ncbi.nlm.nih.gov/pubmed/21917759

215. Santoro, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V., Viviani, S., et.al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study, J Clin Oncol, 2000. 18: p. 2615-9., https://www.ncbi.nlm.nih.gov/pubmed/10893294

216. Helsing, M. D., Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study, Eur J Cancer, 1997. 33: p. 500-2., https://www.ncbi.nlm.nih.gov/pubmed/9155539

217. Boll, B., Borchmann, P., Topp, M. S., Hanel, M., Reiners, K. S., Engert, A., et.al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma, Br J Haematol, 2010. 148: p. 480-2., https://www.ncbi.nlm.nih.gov/pubmed/19863533

218. Younes, Anas, Santoro, Armando, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, et.al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, The Lancet Oncology, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27451390

219. Johnston, P. B., Inwards, D. J., Colgan, J. P., Laplant, B. R., Kabat, B. F., Habermann, T. M., et.al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma, Am J Hematol, 2010. 85: p. 320-4., https://www.ncbi.nlm.nih.gov/pubmed/20229590

220. Armand, P., Shipp, M. A., Ribrag, V., Michot, J. M., Zinzani, P. L., Kuruvilla, J., et.al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure, J Clin Oncol, 2016., https://www.ncbi.nlm.nih.gov/pubmed/27354476

221. Klimm, B., Reineke, T., Haverkamp, H., Behringer, K., Eich, H. T., Josting, A., et.al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group, J Clin Oncol, 2005. 23: p. 8003-11., https://www.ncbi.nlm.nih.gov/pubmed/16204002

222. Herida, M., Mary-Krause, M., Kaphan, R., Cadranel, J., Poizot-Martin, I., Rabaud, C., et.al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients, J Clin Oncol, 2003. 21: p. 3447-53., https://www.ncbi.nlm.nih.gov/pubmed/12972519

223. Powles, T., Robinson, D., Stebbing, J., Shamash, J., Nelson, M., Gazzard, B., et.al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection, J Clin Oncol, 2009. 27: p. 884-90., https://www.ncbi.nlm.nih.gov/pubmed/19114688

224. Hoffmann, C, Hentrich, M, Gillor, D, Behrens, G, Jensen, B, Stoehr, A, et.al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study., HIV Med, 2015. 16 (4)(4): p. 261-4., https://pubmed.ncbi.nlm.nih.gov/25252101/

225. Hoffmann, C, Schommers, P, Wolf, E, Müller, M, Schultze, A, Krznaric, I, et.al. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma., AIDS, 2016. 30 (5)(5): p. 753-60., https://pubmed.ncbi.nlm.nih.gov/26605513/

226. Bohlius, J., Schmidlin, K., Boue, F., Fatkenheuer, G., May, M., Caro-Murillo, A. M., et.al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes, Blood, 2011. 117: p. 6100-8., http://www.bloodjournal.org/content/bloodjournal/117/23/6100.full.pdf

227. Spina, M., Carbone, A., Gloghini, A., Serraino, D., Berretta, M., Tirelli, U., Hodgkin's Disease in Patients with HIV Infection, Adv Hematol, 2011. 2011:, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948898/

228. Castillo, JJ, Bower, M, Brühlmann, J, Novak, U, Furrer, H, Tanaka, PY, et.al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study., Cancer, 2015. 121 (3)(3): p. 423-31., https://pubmed.ncbi.nlm.nih.gov/25251326/

229. Hentrich, M., Maretta, L., Chow, K. U., Bogner, J. R., Schurmann, D., Neuhoff, P., et.al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study, Ann Oncol, 2006. 17: p. 914-9., https://www.ncbi.nlm.nih.gov/pubmed/16565210

230. Hoffmann, C., Chow, K. U., Wolf, E., Faetkenheuer, G., Stellbrink, H. J., van Lunzen, J., et.al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease, Br J Haematol, 2004. 125: p. 455-62., https://www.ncbi.nlm.nih.gov/pubmed/15142115

231. Gerard, L., Galicier, L., Boulanger, E., Quint, L., Lebrette, M. G., Mortier, E., et.al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy, Aids, 2003. 17: p. 81-7., https://www.ncbi.nlm.nih.gov/pubmed/12478072

232. Besson, C., Lancar, R., Prevot, S., Brice, P., Meyohas, M. C., Marchou, B., et.al. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort, Clin Infect Dis, 2015. 61: p. 1469-75., https://www.ncbi.nlm.nih.gov/pubmed/26223997

233. Xicoy, B., Ribera, J. M., Miralles, P., Berenguer, J., Rubio, R., Mahillo, B., et.al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma, Haematologica, 2007. 92: p. 191-8., https://www.ncbi.nlm.nih.gov/pubmed/17296568

234. Montoto, S., Shaw, K., Okosun, J., Gandhi, S., Fields, P., Wilson, A., et.al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era, J Clin Oncol, 2012. 30: p. 4111-6., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320889/pdf/zlj4111.pdf

235. Sorigué, M, García, O, Tapia, G, Baptista, MJ, Moreno, M, Mate, JL, et.al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma., AIDS, 2017. 31 (10)(10): p. 1445-1449., https://pubmed.ncbi.nlm.nih.gov/28574963/

236. Hartmann, P., Rehwald, U., Salzberger, B., Franzen, C., Sieber, M., Wohrmann, A., et.al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection, Ann Oncol, 2003. 14: p. 1562-9., https://www.ncbi.nlm.nih.gov/pubmed/14504059

237. Spina, M., Rossi, G., Antinon, A., Allione, B., Chimienti, E., Talamini, R., et.al. VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV), Ann Oncol, 2008. 19:, https://www.mjhid.org/index.php/mjhid/article/view/2019.004/3580

238. Hentrich, M., Berger, M., Wyen, C., Siehl, J., Rockstroh, J. K., Muller, M., et.al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study, J Clin Oncol, 2012. 30: p. 4117-23., https://www.ncbi.nlm.nih.gov/pubmed/23045592

239. Diez-Martin, J. L., Balsalobre, P., Re, A., Michieli, M., Ribera, J. M., Canals, C., et.al. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation, Blood, 2009. 113: p. 6011-4., http://www.bloodjournal.org/content/bloodjournal/113/23/6011.full.pdf

240. Nogova, L., Reineke, T., Brillant, C., Sieniawski, M., Rudiger, T., Josting, A., et.al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group, J Clin Oncol, 2008. 26: p. 434-9., https://www.ncbi.nlm.nih.gov/pubmed/18086799

241. Eichenauer, D. A., Plutschow, A., Fuchs, M., von Tresckow, B., Boll, B., Behringer, K., et.al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group, J Clin Oncol, 2015. 33: p. 2857-62., https://www.ncbi.nlm.nih.gov/pubmed/26240235

242. Al-Mansour, M., Connors, J. M., Gascoyne, R. D., Skinnider, B., Savage, K. J., Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma, J Clin Oncol, 2010. 28: p. 793-9., https://www.ncbi.nlm.nih.gov/pubmed/20048177

243. Schulz, H., Rehwald, U., Morschhauser, F., Elter, T., Driessen, C., Rudiger, T., et.al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG), Blood, 2008. 111: p. 109-11., http://www.bloodjournal.org/content/bloodjournal/111/1/109.full.pdf

244. Eichenauer, D. A., Goergen, H., Plutschow, A., Wongso, D., Behringer, K., Kreissl, S., et.al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group, Leukemia, 2016. 30: p. 1425-7., http://www.nature.com/leu/journal/v30/n6/pdf/leu2015321a.pdf

245. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., et.al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma, J Clin Oncol, 2014. 32: p. 912-8., https://www.ncbi.nlm.nih.gov/pubmed/24516013

246. Eichenauer, DA, Plütschow, A, Schröder, L, Fuchs, M, Böll, B, von Tresckow, B, et.al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group., Blood, 2018. 132 (14)(14): p. 1519-1525., https://pubmed.ncbi.nlm.nih.gov/30064977/

247. Moshe, Yakir, Bentur, Ohad Shimshon, Lishner, Michael, Avivi, Irit, The management of hodgkin lymphomas in pregnanciesJohn Wiley & Sons, Ltd, European Journal of Haematology, 2017. 99(5): p. 385 - 391., https://doi.org/10.1111/ejh.12956

248. Pereg, D., Koren, G., Lishner, M., The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy, Haematologica, 2007. 92(9): p. 1230-7.

249. Stovall, M., Blackwell, C. R., Cundiff, J., Novack, D. H., Palta, J. R., Wagner, L. K., et.al. Fetal dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task Group No. 36, Med Phys, 1995. 22(1): p. 63-82., https://pubmed.ncbi.nlm.nih.gov/7715571/

250. Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., et.al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients, JAMA Oncol, 2015. 1(8): p. 1145-53., https://pubmed.ncbi.nlm.nih.gov/26247818/

251. Maggen, C., Dierickx, D., Lugtenburg, P., Laenen, A., Cardonick, E., Shmakov, R. G., et.al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study, Lancet Haematol, 2019. 6(11): p. e551-e561., https://pubmed.ncbi.nlm.nih.gov/31564649/

252. Evens, AM, Advani, R, Press, OW, Lossos, IS, Vose, JM, Hernandez-Ilizaliturri, FJ, et.al. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis., J Clin Oncol, 2013. 31 (32)(32): p. 4132-9., https://pubmed.ncbi.nlm.nih.gov/24043736/

253. Mocikova, H., Obrtlikova, P., Vackova, B., Trneny, M., Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study, Ann Oncol, 2010. 21: p. 1222-7., http://www.ncbi.nlm.nih.gov/pubmed/19901011

254. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Berthelsen, A. K., Keiding, S., et.al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma, Haematologica, 2006a. 91: p. 482-9., http://www.haematologica.org/content/haematol/91/4/482.full.pdf

255. Zinzani, P. L., Tani, M., Trisolini, R., Fanti, S., Stefoni, V., Alifano, M., et.al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma, Haematologica, 2007. 92: p. 771-7., http://www.ncbi.nlm.nih.gov/pubmed/17550849, http://www.haematologica.org/content/haematol/92/6/771.full.pdf

256. Lee, A. I., Zuckerman, D. S., Van den Abbeele, A. D., Aquino, S. L., Crowley, D., Toomey, C., et.al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis, Cancer, 2010. 116: p. 3835-42., http://www.ncbi.nlm.nih.gov/pubmed/20564135

257. Jerusalem, G., Beguin, Y., Fassotte, M. F., Belhocine, T., Hustinx, R., Rigo, P., et.al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease, Ann Oncol, 2003. 14: p. 123-30., http://www.ncbi.nlm.nih.gov/pubmed/12488304

258. Zinzani, P. L., Stefoni, V., Tani, M., Fanti, S., Musuraca, G., Castellucci, P., et.al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma, J Clin Oncol, 2009. 27: p. 1781-7., http://www.ncbi.nlm.nih.gov/pubmed/19273712

259. Petrausch, U., Samaras, P., Veit-Haibach, P., Tschopp, A., Soyka, J. D., Knuth, A., et.al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?, Ann Oncol, 2010. 21: p. 1053-7., http://www.ncbi.nlm.nih.gov/pubmed/19914963

260. V, o, l, t, i, n, et.al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18, Ann Oncol, 2018. 29 (9): p. 1926 - 1931.

261. Zinzani, P. L., Tani, M., Trisolini, R., Fanti, S., Stefoni, V., Alifano, M., et.al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma, Haematologica, 2007. 92: p. 771-7., http://www.ncbi.nlm.nih.gov/pubmed/17550849, http://www.haematologica.org/content/haematol/92/6/771.full.pdf

262. Jerusalem, G., Beguin, Y., Fassotte, M. F., Belhocine, T., Hustinx, R., Rigo, P., et.al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease, Ann Oncol, 2003. 14: p. 123-30., http://www.ncbi.nlm.nih.gov/pubmed/12488304

263. Zinzani, P. L., Stefoni, V., Tani, M., Fanti, S., Musuraca, G., Castellucci, P., et.al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma, J Clin Oncol, 2009. 27: p. 1781-7., http://www.ncbi.nlm.nih.gov/pubmed/19273712

264. Mocikova, H., Obrtlikova, P., Vackova, B., Trneny, M., Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study, Ann Oncol, 2010. 21: p. 1222-7., http://www.ncbi.nlm.nih.gov/pubmed/19901011

265. Lee, A. I., Zuckerman, D. S., Van den Abbeele, A. D., Aquino, S. L., Crowley, D., Toomey, C., et.al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis, Cancer, 2010. 116: p. 3835-42., http://www.ncbi.nlm.nih.gov/pubmed/20564135

266. Petrausch, U., Samaras, P., Veit-Haibach, P., Tschopp, A., Soyka, J. D., Knuth, A., et.al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?, Ann Oncol, 2010. 21: p. 1053-7., http://www.ncbi.nlm.nih.gov/pubmed/19914963

267. El-Galaly, TC, Mylam, KJ, Brown, P, Specht, L, Christiansen, I, Munksgaard, L, et.al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs., Haematologica, 2012. 97 (6)(6): p. 931-6., https://pubmed.ncbi.nlm.nih.gov/22207683/

268. Engert, Andreas, Haverkamp, Heinz, Kobe, Carsten, Markova, Jana, Renner, Christoph, Ho, Anthony D., et.al. Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results, ASH Annual Meeting Abstracts, 2011. 118: p. 589-., http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/589

269. Brockelmann, P. J., Muller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., et.al. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma, Ann Oncol, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28327958

270. Devillier, R., Coso, D., Castagna, L., Brenot Rossi, I., Anastasia, A., Chiti, A., et.al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy, Haematologica, 2012. 97: p. 1073-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396680/pdf/0971073.pdf

271. Moskowitz, C. H., Matasar, M. J., Zelenetz, A. D., Nimer, S. D., Gerecitano, J., Hamlin, P., et.al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood, 2012. p. 1665-70., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/360/CN-00897360/frame.html, http://www.bloodjournal.org/content/bloodjournal/119/7/1665.full.pdf

272. Jabbour, E., Hosing, C., Ayers, G., Nunez, R., Anderlini, P., Pro, B., et.al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma, Cancer, 2007. 109: p. 2481-9., https://www.ncbi.nlm.nih.gov/pubmed/17497648

273. Moskowitz, A. J., Yahalom, J., Kewalramani, T., Maragulia, J. C., Vanak, J. M., Zelenetz, A. D., et.al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma, Blood, 2010. 116: p. 4934-7., http://www.ncbi.nlm.nih.gov/pubmed/20733154, http://www.bloodjournal.org/content/bloodjournal/116/23/4934.full.pdf

274. Castagna, L., Bramanti, S., Balzarotti, M., Sarina, B., Todisco, E., Anastasia, A., et.al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy, Br J Haematol, 2009. 145: p. 369-72., https://www.ncbi.nlm.nih.gov/pubmed/19344403

275. Schot, B. W., Zijlstra, J. M., Sluiter, W. J., van Imhoff, G. W., Pruim, J., Vaalburg, W., et.al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma, Blood, 2007. 109: p. 486-91., http://www.ncbi.nlm.nih.gov/pubmed/17003382, http://www.bloodjournal.org/content/bloodjournal/109/2/486.full.pdf

276. Mocikova, H., Pytlik, R., Markova, J., Steinerova, K., Kral, Z., Belada, D., et.al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma, Leuk Lymphoma, 2011. 52: p. 1668-74., http://www.ncbi.nlm.nih.gov/pubmed/21699377, http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.573889?needAccess=true

277. Devillier, R., Coso, D., Castagna, L., Brenot Rossi, I., Anastasia, A., Chiti, A., et.al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy, Haematologica, 2012. 97: p. 1073-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396680/pdf/0971073.pdf

278. Moskowitz, C. H., Matasar, M. J., Zelenetz, A. D., Nimer, S. D., Gerecitano, J., Hamlin, P., et.al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood, 2012. p. 1665-70., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/360/CN-00897360/frame.html, http://www.bloodjournal.org/content/bloodjournal/119/7/1665.full.pdf

279. Adams, H. J., Kwee, T. C., Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis, Ann Hematol, 2016. 95: p. 695-706., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819743/pdf/277_2016_Article_2619.pdf

280. Brockelmann, P. J., Muller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., et.al. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma, Ann Oncol, 2017., https://www.ncbi.nlm.nih.gov/pubmed/28327958

281. Sucak, G. T., Ozkurt, Z. N., Suyani, E., Yasar, D. G., Akdemir, O. U., Aki, Z., et.al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival, Ann Hematol, 2011. 90: p. 1329-36., https://www.ncbi.nlm.nih.gov/pubmed/21437590

282. Palmer, J., Goggins, T., Broadwater, G., Chao, N., Horwitz, M., Beaven, A., et.al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma, Bone Marrow Transplant, 2011. 46: p. 847-51., http://www.ncbi.nlm.nih.gov/pubmed/20856212, http://www.nature.com/bmt/journal/v46/n6/pdf/bmt2010203a.pdf

283. Sucak, G. T., Ozkurt, Z. N., Suyani, E., Yasar, D. G., Akdemir, O. U., Aki, Z., et.al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival, Ann Hematol, 2011. 90: p. 1329-36., https://www.ncbi.nlm.nih.gov/pubmed/21437590

284. Palmer, J., Goggins, T., Broadwater, G., Chao, N., Horwitz, M., Beaven, A., et.al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma, Bone Marrow Transplant, 2011. 46: p. 847-51., http://www.ncbi.nlm.nih.gov/pubmed/20856212, http://www.nature.com/bmt/journal/v46/n6/pdf/bmt2010203a.pdf

285. Rancea, Michaela, Monsef, Ina, von Tresckow, Bastian, Engert, Andreas, Skoetz, Nicole, High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23784872

286. Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B., McMillan, A., et.al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial, Lancet, 1993. 341: p. 1051-4., http://www.ncbi.nlm.nih.gov/pubmed/8096958

287. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., et.al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet, 2002. 359: p. 2065-71., http://www.ncbi.nlm.nih.gov/pubmed/12086759

288. Rancea, Michaela, Monsef, Ina, von Tresckow, Bastian, Engert, Andreas, Skoetz, Nicole, High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2013., https://www.ncbi.nlm.nih.gov/pubmed/23784872

289. Josting, A., Muller, H., Borchmann, P., Baars, J. W., Metzner, B., Dohner, H., et.al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma, J Clin Oncol, 2010. 28: p. 5074-80., http://www.ncbi.nlm.nih.gov/pubmed/20975066

290. Puig, N., Pintilie, M., Seshadri, T., Al-Farsi, K., Franke, N., Keating, A., et.al. High-dose chemotherapy and ASCT in elderly patients with Hodgkin's lymphoma, Bone Marrow Transplant, 2011., http://www.ncbi.nlm.nih.gov/pubmed/21243027, http://www.nature.com/bmt/journal/v46/n10/pdf/bmt2010294a.pdf

291. Boll, Boris, Gorgen, Helen, Arndt, Nils, Plutschow, Annette, Fuchs, Michael, Diehl, Volker, et.al. Relapsed Hodgkin Lymphoma in Elderly Patients: A Comprehensive Analysis From the German Hodgkin Study Group (GHSG), ASH Annual Meeting Abstracts, 2011. 118: p. 92-., http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/92

292. Smith, S. M., van Besien, K., Carreras, J., Bashey, A., Cairo, M. S., Freytes, C. O., et.al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant, Biol Blood Marrow Transplant, 2008. 14: p. 904-12., http://www.ncbi.nlm.nih.gov/pubmed/18640574

293. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., et.al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet, 2002. 359: p. 2065-71., http://www.ncbi.nlm.nih.gov/pubmed/12086759

294. Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H. H., et.al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease, Ann Oncol, 2002. 13: p. 1628-35., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12377653

295. Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., et.al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma, Haematologica, 2007. 92: p. 35-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17229633, http://www.haematologica.org/content/haematol/92/1/35.full.pdf

296. Crump, M., Kuruvilla, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., et.al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12, J Clin Oncol, 2014. 32(31): p. 3490-6., https://pubmed.ncbi.nlm.nih.gov/25267740/

297. Moccia, A. A., Hitz, F., Hoskins, P., Klasa, R., Power, M. M., Savage, K. J., et.al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma, Leuk Lymphoma, 2017. 58(2): p. 324-332., https://pubmed.ncbi.nlm.nih.gov/27347845/

298. Josting, A., Muller, H., Borchmann, P., Baars, J. W., Metzner, B., Dohner, H., et.al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma, J Clin Oncol, 2010. 28: p. 5074-80., http://www.ncbi.nlm.nih.gov/pubmed/20975066

299. Walewski, J., Nademanee, A., Masszi, T., Holowiecki, J., Abidi, M., Chen, A., et.al. Multivariate analysis of PFS from the aethera trial: A phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL, Haematologica, 2015. p. 322-3., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/114/CN-01108114/frame.html

300. Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., et.al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma, J Clin Oncol, 2017. p. Jco2016721316., https://www.ncbi.nlm.nih.gov/pubmed/28441111

301. Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., et.al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087, Blood, 2019. 134(14): p. 1144-1153., https://pubmed.ncbi.nlm.nih.gov/31409671/

302. Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H. H., et.al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease, Ann Oncol, 2002. 13: p. 1628-35., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12377653

303. Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., et.al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma, Haematologica, 2007. 92: p. 35-41., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17229633, http://www.haematologica.org/content/haematol/92/1/35.full.pdf

304. Crump, M., Kuruvilla, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., et.al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12, J Clin Oncol, 2014. 32(31): p. 3490-6., https://pubmed.ncbi.nlm.nih.gov/25267740/

305. Moccia, A. A., Hitz, F., Hoskins, P., Klasa, R., Power, M. M., Savage, K. J., et.al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma, Leuk Lymphoma, 2017. 58(2): p. 324-332., https://pubmed.ncbi.nlm.nih.gov/27347845/

306. Moskowitz, A. J., Schoder, H., Yahalom, J., McCall, S. J., Fox, S. Y., Gerecitano, J., et.al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, Lancet Oncol, 2015. 16: p. 284-92., https://www.ncbi.nlm.nih.gov/pubmed/25683846

307. Chen, R., Palmer, J. M., Martin, P., Tsai, N., Kim, Y., Chen, B. T., et.al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma, Biol Blood Marrow Transplant, 2015. 21: p. 2136-40., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639410/pdf/nihms723908.pdf

308. Brandwein, J. M., Callum, J., Sutcliffe, S. B., Scott, J. G., Keating, A., Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease, Bone Marrow Transplant, 1990. 5: p. 99-103., http://www.ncbi.nlm.nih.gov/pubmed/2310878

309. Stewart, A. K., Brandwein, J. M., Sutcliffe, S. B., Scott, J. G., Keating, A., Mini-beam as Salvage Chemotherapy for Refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma, Leuk Lymphoma, 1991. 5: p. 111-5., http://www.ncbi.nlm.nih.gov/pubmed/21269069, http://www.tandfonline.com/doi/pdf/10.3109/10428199109068113?needAccess=true

310. Walewski, J, Hellmann, A, Siritanaratkul, N, Ozsan, GH, Ozcan, M, Chuncharunee, S, et.al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy., Br J Haematol, 2018. 183 (3)(3): p. 400-410., https://pubmed.ncbi.nlm.nih.gov/30168134/

311. Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., Kennedy, D. A., et.al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies, Oncologist, 2012. 17: p. 1073-80., https://www.ncbi.nlm.nih.gov/pubmed/22855426

312. Sasse, S., Rothe, A., Goergen, H., Eichenauer, D. A., Lohri, A., Kreher, S., et.al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma, Leuk Lymphoma, 2013. 54: p. 2144-8., http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.775434?needAccess=true

313. Zinzani, P. L., Pellegrini, C., Cantonetti, M., Re, A., Pinto, A., Pavone, V., et.al. Brentuximab Vedotin in Transplant-Naive Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients, Oncologist, 2015. 20: p. 1413-6., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679088/pdf/theoncologist_15227.pdf

314. Gibb, A., Jones, C., Bloor, A., Kulkarni, S., Illidge, T., Linton, K., et.al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center, Haematologica, 2013. 98: p. 611-4., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659993/pdf/0980611.pdf

315. Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., et.al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma, J Clin Oncol, 2017. p. Jco2016721316., https://www.ncbi.nlm.nih.gov/pubmed/28441111

316. Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., et.al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087, Blood, 2019. 134(14): p. 1144-1153., https://pubmed.ncbi.nlm.nih.gov/31409671/

317. Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B., McMillan, A., et.al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial, Lancet, 1993. 341: p. 1051-4., http://www.ncbi.nlm.nih.gov/pubmed/8096958

318. Morschhauser, F., Brice, P., Ferme, C., Divine, M., Salles, G., Bouabdallah, R., et.al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group, J Clin Oncol, 2008. 26: p. 5980-7., https://www.ncbi.nlm.nih.gov/pubmed/19018090

319. Sibon, D., Morschhauser, F., Resche-Rigon, M., Ghez, D., Dupuis, J., Marcais, A., et.al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group, Haematologica, 2016. 101: p. 474-81., http://www.haematologica.org/content/haematol/101/4/474.full.pdf

320. Reece, D. E., Barnett, M. J., Shepherd, J. D., Hogge, D. E., Klasa, R. J., Nantel, S. H., et.al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy, Blood, 1995. 86: p. 451-6., http://www.ncbi.nlm.nih.gov/pubmed/7541661, http://www.bloodjournal.org/content/bloodjournal/86/2/451.full.pdf

321. Crump, M., Smith, A. M., Brandwein, J., Couture, F., Sherret, H., Sutton, D. M., et.al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant, J Clin Oncol, 1993. 11: p. 704-11., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8478664

322. Morschhauser, F., Brice, P., Ferme, C., Divine, M., Salles, G., Bouabdallah, R., et.al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group, J Clin Oncol, 2008. 26: p. 5980-7., https://www.ncbi.nlm.nih.gov/pubmed/19018090

323. Sibon, D., Morschhauser, F., Resche-Rigon, M., Ghez, D., Dupuis, J., Marcais, A., et.al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group, Haematologica, 2016. 101: p. 474-81., http://www.haematologica.org/content/haematol/101/4/474.full.pdf

324. Moskowitz, A. J., Schoder, H., Yahalom, J., McCall, S. J., Fox, S. Y., Gerecitano, J., et.al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, Lancet Oncol, 2015. 16: p. 284-92., https://www.ncbi.nlm.nih.gov/pubmed/25683846

325. Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., et.al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse, Blood, 2018. 132(25): p. 2639-2642., https://pubmed.ncbi.nlm.nih.gov/30266774/

326. Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., et.al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse, Blood, 2018. 132(25): p. 2639-2642., https://pubmed.ncbi.nlm.nih.gov/30266774/

327. Josting, A., Nogova, L., Franklin, J., Glossmann, J. P., Eich, H. T., Sieber, M., et.al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group, J Clin Oncol, 2005. 23: p. 1522-9., http://www.ncbi.nlm.nih.gov/pubmed/15632410

328. Ruffer, J. U., Ballova, V., Glossmann, J., Sieber, M., Franklin, J., Nogova, L., et.al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group, Leuk Lymphoma, 2005. 46: p. 1561-7., http://www.ncbi.nlm.nih.gov/pubmed/16236610, http://www.tandfonline.com/doi/pdf/10.1080/10428190500178167?needAccess=true

329. Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., et.al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 2012. 30: p. 2183-9., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646316/pdf/zlj2183.pdf

330. Santoro, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V., Viviani, S., et.al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study, J Clin Oncol, 2000. 18: p. 2615-9., https://www.ncbi.nlm.nih.gov/pubmed/10893294

331. Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., et.al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, Blood, 2016. 128(12): p. 1562-6., https://pubmed.ncbi.nlm.nih.gov/27432875/

332. Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., et.al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial, J Clin Oncol, 2018. 36(14): p. 1428-1439., https://pubmed.ncbi.nlm.nih.gov/29584546/

333. Josting, A., Nogova, L., Franklin, J., Glossmann, J. P., Eich, H. T., Sieber, M., et.al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group, J Clin Oncol, 2005. 23: p. 1522-9., http://www.ncbi.nlm.nih.gov/pubmed/15632410

334. Ruffer, J. U., Ballova, V., Glossmann, J., Sieber, M., Franklin, J., Nogova, L., et.al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group, Leuk Lymphoma, 2005. 46: p. 1561-7., http://www.ncbi.nlm.nih.gov/pubmed/16236610, http://www.tandfonline.com/doi/pdf/10.1080/10428190500178167?needAccess=true

335. Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., et.al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, Blood, 2016. 128(12): p. 1562-6., https://pubmed.ncbi.nlm.nih.gov/27432875/

336. Devizzi, L., Santoro, A., Bonfante, V., Viviani, S., Balzarini, L., Valagussa, P., et.al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease, Ann Oncol, 1994. 5: p. 817-20., http://www.ncbi.nlm.nih.gov/pubmed/7531487

337. Little, R., Wittes, R. E., Longo, D. L., Wilson, W. H., Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant, J Clin Oncol, 1998. 16: p. 584-8., http://www.ncbi.nlm.nih.gov/pubmed/9469345

338. Moskowitz, A. J., Hamlin, P. A., Jr., Perales, M. A., Gerecitano, J., Horwitz, S. M., Matasar, M. J., et.al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma, J Clin Oncol, 2013. 31: p. 456-60., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862960/pdf/zlj456.pdf

339. Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., et.al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial, J Clin Oncol, 2018. 36(14): p. 1428-1439., https://pubmed.ncbi.nlm.nih.gov/29584546/

340. Milpied, N., Fielding, A. K., Pearce, R. M., Ernst, P., Goldstone, A. H., Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation, J Clin Oncol, 1996. 14: p. 1291-6., http://www.ncbi.nlm.nih.gov/pubmed/8648386

341. Gajewski, J. L., Phillips, G. L., Sobocinski, K. A., Armitage, J. O., Gale, R. P., Champlin, R. E., et.al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease, J Clin Oncol, 1996. 14: p. 572-8., http://www.ncbi.nlm.nih.gov/pubmed/8636773

342. Akpek, G., Ambinder, R. F., Piantadosi, S., Abrams, R. A., Brodsky, R. A., Vogelsang, G. B., et.al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma, J Clin Oncol, 2001. 19: p. 4314-21., http://www.ncbi.nlm.nih.gov/pubmed/11731514

343. Genadieva-Stavrik, S., Boumendil, A., Dreger, P., Peggs, K., Briones, J., Corradini, P., et.al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, Ann Oncol, 2016. 27(12): p. 2251-2257., https://pubmed.ncbi.nlm.nih.gov/28007754/

344. Martino, M., Festuccia, M., Fedele, R., Console, G., Cimminiello, M., Gavarotti, P., et.al. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents, Expert Opin Biol Ther, 2016. 16(3): p. 347-64., https://pubmed.ncbi.nlm.nih.gov/26652934/

345. Gauthier, J., Castagna, L., Garnier, F., Guillaume, T., Socie, G., Maury, S., et.al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy, Bone Marrow Transplant, 2017. 52: p. 689-696., http://www.nature.com/bmt/journal/v52/n5/pdf/bmt2016349a.pdf

346. Gauthier, J., Poiré, X., Gac, A. C., Leclerc, M., Guillaume, T., Chalandon, Y., et.al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, Bone Marrow Transplant, 2018. 53(4): p. 400-409., https://pubmed.ncbi.nlm.nih.gov/29330405/

347. Gayoso, J., Balsalobre, P., Pascual, M. J., Castilla-Llorente, C., López-Corral, L., Kwon, M., et.al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience, Bone Marrow Transplant, 2016. 51(10): p. 1307-1312., https://pubmed.ncbi.nlm.nih.gov/27159177/

348. Giaccone, L., Festuccia, M., Zallio, F., Sorasio, R., Brunello, L., Maffini, E., et.al. Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma, Bone Marrow Transplant, 2017. 52(8): p. 1208-1211., https://pubmed.ncbi.nlm.nih.gov/28581461/

349. Lacerda, M. P., Arrais Rodrigues, C., Pereira, A. D., Novis, Y., Fonseca, M., Silva, R. L., et.al. Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis, Biol Blood Marrow Transplant, 2017. 23(4): p. 705-707., https://pubmed.ncbi.nlm.nih.gov/28108270/

350. Mariotti, J., Devillier, R., Bramanti, S., Sarina, B., Furst, S., Granata, A., et.al. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors, Biol Blood Marrow Transplant, 2018. 24(3): p. 627-632., https://pubmed.ncbi.nlm.nih.gov/29197681/

351. Rashidi, A., Ebadi, M., Cashen, A. F., Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis, Bone Marrow Transplant, 2016. 51(4): p. 521-8., https://pubmed.ncbi.nlm.nih.gov/26726948/

352. Messer, M., Steinzen, A., Vervolgyi, E., Lerch, C., Richter, B., Dreger, P., et.al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review, Leukemia & Lymphoma, 2014. 55: p. 296-306., https://www.tandfonline.com/doi/abs/10.3109/10428194.2013.802780

353. Bachanova, V., Burns, L. J., Wang, T., Carreras, J., Gale, R. P., Wiernik, P. H., et.al. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor, Bone Marrow Transplantation, 2015. 50: p. 197-203., https://www.ncbi.nlm.nih.gov/pubmed/25402415

354. Bachanova, V., Burns, L. J., Wang, T., Carreras, J., Gale, R. P., Wiernik, P. H., et.al. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor, Bone Marrow Transplant, 2015. 50(2): p. 197-203., https://pubmed.ncbi.nlm.nih.gov/25402415/

355. Genadieva-Stavrik, S., Boumendil, A., Dreger, P., Peggs, K., Briones, J., Corradini, P., et.al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, Ann Oncol, 2016. 27(12): p. 2251-2257., https://pubmed.ncbi.nlm.nih.gov/28007754/

356. Martino, M., Festuccia, M., Fedele, R., Console, G., Cimminiello, M., Gavarotti, P., et.al. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents, Expert Opin Biol Ther, 2016. 16(3): p. 347-64., https://pubmed.ncbi.nlm.nih.gov/26652934/

357. Milpied, N., Fielding, A. K., Pearce, R. M., Ernst, P., Goldstone, A. H., Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation, J Clin Oncol, 1996. 14: p. 1291-6., http://www.ncbi.nlm.nih.gov/pubmed/8648386

358. Gajewski, J. L., Phillips, G. L., Sobocinski, K. A., Armitage, J. O., Gale, R. P., Champlin, R. E., et.al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease, J Clin Oncol, 1996. 14: p. 572-8., http://www.ncbi.nlm.nih.gov/pubmed/8636773

359. Akpek, G., Ambinder, R. F., Piantadosi, S., Abrams, R. A., Brodsky, R. A., Vogelsang, G. B., et.al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma, J Clin Oncol, 2001. 19: p. 4314-21., http://www.ncbi.nlm.nih.gov/pubmed/11731514

360. Sureda, A., Robinson, S., Canals, C., Carella, A. M., Boogaerts, M. A., Caballero, D., et.al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, J Clin Oncol, 2008. 26: p. 455-62., http://www.ncbi.nlm.nih.gov/pubmed/18086796

361. Gauthier, J., Castagna, L., Garnier, F., Guillaume, T., Socie, G., Maury, S., et.al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy, Bone Marrow Transplant, 2017. 52: p. 689-696., http://www.nature.com/bmt/journal/v52/n5/pdf/bmt2016349a.pdf

362. Gayoso, J., Balsalobre, P., Pascual, M. J., Castilla-Llorente, C., López-Corral, L., Kwon, M., et.al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience, Bone Marrow Transplant, 2016. 51(10): p. 1307-1312., https://pubmed.ncbi.nlm.nih.gov/27159177/

363. Giaccone, L., Festuccia, M., Zallio, F., Sorasio, R., Brunello, L., Maffini, E., et.al. Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma, Bone Marrow Transplant, 2017. 52(8): p. 1208-1211., https://pubmed.ncbi.nlm.nih.gov/28581461/

364. Lacerda, M. P., Arrais Rodrigues, C., Pereira, A. D., Novis, Y., Fonseca, M., Silva, R. L., et.al. Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Analysis, Biol Blood Marrow Transplant, 2017. 23(4): p. 705-707., https://pubmed.ncbi.nlm.nih.gov/28108270/

365. Mariotti, J., Devillier, R., Bramanti, S., Sarina, B., Furst, S., Granata, A., et.al. T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors, Biol Blood Marrow Transplant, 2018. 24(3): p. 627-632., https://pubmed.ncbi.nlm.nih.gov/29197681/

366. Rashidi, A., Ebadi, M., Cashen, A. F., Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis, Bone Marrow Transplant, 2016. 51(4): p. 521-8., https://pubmed.ncbi.nlm.nih.gov/26726948/

367. Gauthier, J., Poiré, X., Gac, A. C., Leclerc, M., Guillaume, T., Chalandon, Y., et.al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, Bone Marrow Transplant, 2018. 53(4): p. 400-409., https://pubmed.ncbi.nlm.nih.gov/29330405/

368. Robinson, S. P., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., et.al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome, Haematologica, 2009. 94: p. 230-8., http://www.ncbi.nlm.nih.gov/pubmed/19066328, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635413/pdf/0940230.pdf

369. Sureda, A., Canals, C., Arranz, R., Caballero, D., Ribera, J. M., Brune, M., et.al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, Haematologica, 2012. 97: p. 310-7., https://www.ncbi.nlm.nih.gov/pubmed/21993674

370. Peggs, K. S., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., et.al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation, Lancet, 2005. 365: p. 1934-41., http://www.ncbi.nlm.nih.gov/pubmed/15936420

371. Gauthier, J., Poiré, X., Gac, A. C., Leclerc, M., Guillaume, T., Chalandon, Y., et.al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, Bone Marrow Transplant, 2018. 53(4): p. 400-409., https://pubmed.ncbi.nlm.nih.gov/29330405/

372. Bachanova, V., Burns, L. J., Wang, T., Carreras, J., Gale, R. P., Wiernik, P. H., et.al. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor, Bone Marrow Transplantation, 2015. 50: p. 197-203., https://www.ncbi.nlm.nih.gov/pubmed/25402415

373. Messer, M., Steinzen, A., Vervolgyi, E., Lerch, C., Richter, B., Dreger, P., et.al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review, Leukemia & Lymphoma, 2014. 55: p. 296-306., https://www.tandfonline.com/doi/abs/10.3109/10428194.2013.802780

374. Knips, L., Bergenthal, N., Streckmann, F., Monsef, I., Elter, T., Skoetz, N., Aerobic physical exercise for adult patients with haematological malignancies, Cochrane Database Syst Rev, 2019. 1(1): p. Cd009075., https://pubmed.ncbi.nlm.nih.gov/30702150/

375. Knips, L., Bergenthal, N., Streckmann, F., Monsef, I., Elter, T., Skoetz, N., Aerobic physical exercise for adult patients with haematological malignancies, Cochrane Database Syst Rev, 2019. 1(1): p. Cd009075., https://pubmed.ncbi.nlm.nih.gov/30702150/

376. Gafter-Gvili, A., Fraser, A., Paul, M., Vidal, L., Lawrie, T. A., van de Wetering, M. D., et.al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy, Cochrane Database Syst Rev, 2012. 1: p. Cd004386., https://www.ncbi.nlm.nih.gov/pubmed/22258955

377. Cullen, M., Baijal, S., Prevention of febrile neutropenia: use of prophylactic antibiotics, Br J Cancer, 2009. 101 Suppl 1: p. S11-4., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752225/pdf/6605270a.pdf

378. Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., et.al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas, N Engl J Med, 2005. 353: p. 988-98., http://www.nejm.org/doi/pdf/10.1056/NEJMoa050078

379. Leibovici, L., Paul, M., Cullen, M., Bucaneve, G., Gafter-Gvili, A., Fraser, A., et.al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions, Cancer, 2006. 107: p. 1743-51., http://onlinelibrary.wiley.com/store/10.1002/cncr.22205/asset/22205_ftp.pdf?v=1&t=j7vpmo7t&s=281032531643b51a4e79b649b1917128455a6479

380. Gafter-Gvili, A., Fraser, A., Paul, M., Leibovici, L., Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients, Ann Intern Med, 2005. 142: p. 979-95., https://www.ncbi.nlm.nih.gov/pubmed/15968013

381. Gafter-Gvili, A., Fraser, A., Paul, M., van de Wetering, M., Kremer, L., Leibovici, L., Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy, Cochrane Database Syst Rev, 2005. p. CD004386., http://www.ncbi.nlm.nih.gov/pubmed/16235360

382. Gafter-Gvili, A., Paul, M., Fraser, A., Leibovici, L., Antibiotic prophylaxis in neutropenic patients, Isr Med Assoc J, 2007. 9: p. 460-2., https://www.ncbi.nlm.nih.gov/pubmed/16977651

383. van de Wetering, M. D., de Witte, M. A., Kremer, L. C., Offringa, M., Scholten, R. J., Caron, H. N., Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials, Eur J Cancer, 2005. 41: p. 1372-82., https://www.ncbi.nlm.nih.gov/pubmed/15913983

384. Gafter-Gvili, A., Fraser, A., Paul, M., Vidal, L., Lawrie, T. A., van de Wetering, M. D., et.al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy, Cochrane Database Syst Rev, 2012. 1: p. Cd004386., https://www.ncbi.nlm.nih.gov/pubmed/22258955

385. Bohlius, J., Herbst, C., Reiser, M., Schwarzer, G., Engert, A., Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma, Cochrane Database Syst Rev, 2008. p. CD003189., http://www.ncbi.nlm.nih.gov/pubmed/18843642

386. Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N., et.al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours, Eur J Cancer, 2011. 47: p. 8-32., https://www.ncbi.nlm.nih.gov/pubmed/21095116

387. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dorken, B., Ludwig, W. D., et.al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study, J Clin Oncol, 2009. 27: p. 4548-54., http://jco.ascopubs.org/content/27/27/4548.full.pdf

388. Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Klasa, Richard, et.al. Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma, ASH Annual Meeting Abstracts, 2010. 116: p. 283-., http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/283

389. Tonia, Thomy, Mettler, Annette, Robert, Nadège, Schwarzer, Guido, Seidenfeld, Jerome, Weingart, Olaf, et.al. Erythropoietin or darbepoetin for patients with cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2012., https://www.ncbi.nlm.nih.gov/pubmed/23235597

390. Bohlius, J., Herbst, C., Reiser, M., Schwarzer, G., Engert, A., Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma, Cochrane Database Syst Rev, 2008. p. CD003189., http://www.ncbi.nlm.nih.gov/pubmed/18843642

391. Evens, A. M., Cilley, J., Ortiz, T., Gounder, M., Hou, N., Rademaker, A., et.al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis, Br J Haematol, 2007. 137: p. 545-52., https://www.ncbi.nlm.nih.gov/pubmed/17459049

392. Nangalia, J., Smith, H., Wimperis, J. Z., Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support, Leuk Lymphoma, 2008. 49: p. 1530-6., http://www.tandfonline.com/doi/pdf/10.1080/10428190802210718?needAccess=true

393. Boleti, E., Mead, G. M., ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors, Ann Oncol, 2007. 18: p. 376-80., https://www.ncbi.nlm.nih.gov/pubmed/17071938

394. Minuk, L. A., Monkman, K., Chin-Yee, I. H., Lazo-Langner, A., Bhagirath, V., Chin-Yee, B. H., et.al. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study, Leuk Lymphoma, 2011., http://www.ncbi.nlm.nih.gov/pubmed/21740297

395. Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N., et.al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours, Eur J Cancer, 2011. 47: p. 8-32., https://www.ncbi.nlm.nih.gov/pubmed/21095116

396. Engert, A., Bredenfeld, H., Dohner, H., Ho, A. D., Schmitz, N., Berger, D., et.al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study, Haematologica, 2006. 91: p. 546-9., http://www.haematologica.org/content/haematol/91/4/546.full.pdf

397. Engel, C., Loeffler, M., Schmitz, S., Tesch, H., Diehl, V., Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG), Ann Oncol, 2000. 11: p. 1105-14., https://www.ncbi.nlm.nih.gov/pubmed/11061603

398. Faber, E., Pytlik, R., Slaby, J., Zapletalova, J., Kozak, T., Raida, L., et.al. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial, Eur J Haematol, 2006. 77: p. 493-500., https://www.ncbi.nlm.nih.gov/pubmed/17042769

399. Vanstraelen, G., Frere, P., Ngirabacu, M. C., Willems, E., Fillet, G., Beguin, Y., Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation, Exp Hematol, 2006. 34: p. 382-8., http://orbi.ulg.ac.be/bitstream/2268/6315/1/Neulasta-AutoPBSC-Exp.Hematol.pdf

400. Tonia, Thomy, Mettler, Annette, Robert, Nadège, Schwarzer, Guido, Seidenfeld, Jerome, Weingart, Olaf, et.al. Erythropoietin or darbepoetin for patients with cancerJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2012., https://www.ncbi.nlm.nih.gov/pubmed/23235597

401. Glossmann, J. P., Engert, A., Wassmer, G., Flechtner, H., Ko, Y., Rudolph, C., et.al. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial, Ann Hematol, 2003. 82: p. 469-75., https://link.springer.com/content/pdf/10.1007%2Fs00277-003-0695-0.pdf

402. Chao, N. J., Schriber, J. R., Long, G. D., Negrin, R. S., Catolico, M., Brown, B. W., et.al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation, Blood, 1994. 83: p. 2823-8., http://www.bloodjournal.org/content/bloodjournal/83/10/2823.full.pdf

403. Roila, F., Molassiotis, A., Herrstedt, J., Aapro, M., Gralla, R. J., Bruera, E., et.al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients, Ann Oncol, 2016. 27: p. v119-v133., https://www.ncbi.nlm.nih.gov/pubmed/27664248

404. Herrstedt, J., Roila, F., Warr, D., Celio, L., Navari, R. M., Hesketh, P. J., et.al. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy, Support Care Cancer, 2017. 25: p. 277-288., https://link.springer.com/content/pdf/10.1007%2Fs00520-016-3313-0.pdf

405. Roila, F., Warr, D., Hesketh, P. J., Gralla, R., Herrstedt, J., Jordan, K., et.al. Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy, Support Care Cancer, 2017. 25: p. 295-296., https://link.springer.com/content/pdf/10.1007%2Fs00520-016-3405-x.pdf

406. Lillevang, ST, Andersen, CB, Schmidt, KG, Riisom, K, [Transfusion-associated graft-vs-host disease in a patient with Hodgkin's disease], Ugeskr Laeger, 1992. 154: p. p2979-80., https://www.ncbi.nlm.nih.gov/pubmed/1462387

407. Baglin, TP, Joysey, VC, Horsford, J, Johnson, RT, Broadbent, V, Marcus, RE, Transfusion-associated graft-versus-host disease in patients with Hodgkin's disease and T cell lymphoma., Transfus Med, 1992. 2: p. p195-9., https://www.ncbi.nlm.nih.gov/pubmed/1308830

408. Decoste, SD, Boudreaux, C, Dover, JS, Transfusion-associated graft-vs-host disease in patients with malignancies. Report of two cases and review of the literature [see comments], Arch Dermatol, 1990. 126: p. p1324-9., https://www.ncbi.nlm.nih.gov/pubmed/2221937

409. Haverkamp, H., Boll, B., Eichenauer, D. A., Sasse, S., Fuchs, M., Borchmann, P., et.al. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials, J Clin Oncol, 2015. 33(22): p. 2430-6., https://pubmed.ncbi.nlm.nih.gov/26101245/

410. Aisner, J, Wiernik, PH, Pearl, P, Pregnancy outcome in patients treated for Hodgkin's disease., J Clin Oncol, 1993. 11: p. p507-12., https://www.ncbi.nlm.nih.gov/pubmed/8445425

411. Blatt, J., Pregnancy outcome in long-term survivors of childhood cancer, Med Pediatr Oncol, 1999. 33: p. 29-33., https://www.ncbi.nlm.nih.gov/pubmed/10401494

412. Byrne, J., Rasmussen, S. A., Steinhorn, S. C., Connelly, R. R., Myers, M. H., Lynch, C. F., et.al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer, Am J Hum Genet, 1998. 62: p. 45-52., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1376803/

413. Chow, E. J., Kamineni, A., Daling, J. R., Fraser, A., Wiggins, C. L., Mineau, G. P., et.al. Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis, Arch Pediatr Adolesc Med, 2009. 163: p. 887-94., http://archpedi.jamanetwork.com/data/journals/peds/5165/poa90028_887_894.pdf

414. Green, D. M., Sklar, C. A., Boice, J. D., Jr., Mulvihill, J. J., Whitton, J. A., Stovall, M., et.al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study, J Clin Oncol, 2009. 27: p. 2374-81., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677923/pdf/zlj2374.pdf

415. Janov, AJ, Anderson, J, Cella, DF, Zuckerman, E, Kornblith, AB, Holland, JC, et.al. Pregnancy outcome in survivors of advanced Hodgkin disease [published erratum appears in Cancer 1993 Jan 15; 71(2):492], Cancer, 1992. 70: p. p688-92., https://www.ncbi.nlm.nih.gov/pubmed/1394054

416. Balcerek, M., Behringer, K., Borgmann-Staudt, A., Bürkle, C., Fehm, T., Fey, M., et.al. Perspektive Fertilität Indikation und Durchführung fertilitätsprotektiver Massnahmen bei onkologischen und nicht-onkologischen ErkrankungenM. von Wolf, 2016.

417. Behringer, K., Muller, H., Gorgen, H., Flechtner, H. H., Brillant, C., Halbsguth, T. V., et.al. Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group, British journal of cancer, 2013. 108: p. 49-57., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553532/

418. Anderson, Richard A, Remedios, Rachel, Kirkwood, Amy A, Patrick, Pip, Stevens, Linsey, Clifton-Hadley, Laura, et.al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialElsevier, The Lancet Oncology, 2018. 19(10): p. 1328 - 1337., https://doi.org/10.1016/S1470-2045(18)30500-X

419. Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibi, A. S., Rosenbrock, J., Fertlity and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial, Annals of Oncology, 2012. p. 1818-25., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/402/CN-00853402/frame.html

420. Blumenfeld, Z., Zur, H., Mischari, O., Schultz, N., Balbir-Gurman, A., Cotreatment with GNRH-agonist before and in parallel to gonadotoxic chemotherapy significantly preserves fertility and increases pregnancy rate in addition to cyclic ovarian function, Reproductive sciences (Thousand Oaks, Calif.), 2014. p. 226a., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/610/CN-01061610/frame.html, http://rsx.sagepub.com/content/21/3_suppl/71A.full.pdf

421. Del Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S., et.al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial, JAMA, 2011. 306: p. 269-76., https://www.ncbi.nlm.nih.gov/pubmed/21771987

422. Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachee, P., et.al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial, J Clin Oncol, 2016. 34: p. 2568-74., http://jco.ascopubs.org/content/34/22/2568.full.pdf

423. Karimi Zarchi, M., Forat-Yazdi, M., Nakhai-Moghadam, M., Teimoori, S., Soltani, H., Ovarian function preservation by GnRH agonists during chemotherapy with cyclophosphamide in breast cancer patients- A double blind randomized control trial clinical, Iranian Journal of Reproductive Medicine, 2012. p. 10., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/900/CN-01091900/frame.html

424. Sverrisdottir, A., Nystedt, M., Johansson, H., Fornander, T., Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial, Breast Cancer Res Treat, 2009. 117: p. 561-7., http://www.ncbi.nlm.nih.gov/pubmed/19153828, https://link.springer.com/content/pdf/10.1007%2Fs10549-009-0313-5.pdf

425. Wilson, C., Gossiel, F., Leonard, R., Anderson, R. A., Adamson, D. J. A., Thomas, G., et.al. Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover, Journal of Bone Oncology, 2016. p. 43-9., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/963/CN-01137963/frame.html

426. Donnez, J., Dolmans, M. M., Preservation of fertility in females with haematological malignancy, Br J Haematol, 2011. 154: p. 175-84., https://www.ncbi.nlm.nih.gov/pubmed/21564077

427. von Wolff, M., Donnez, J., Hovatta, O., Keros, V., Maltaris, T., Montag, M., et.al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy--a technique in its infancy but already successful in fertility preservation, Eur J Cancer, 2009. 45: p. 1547-53., https://www.ncbi.nlm.nih.gov/pubmed/19264478

428. Donnez, J., Dolmans, M. M., Pellicer, A., Diaz-Garcia, C., Sanchez Serrano, M., Schmidt, K. T., et.al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation, Fertil Steril, 2013. 99(6): p. 1503-13., https://pubmed.ncbi.nlm.nih.gov/23635349/

429. Chen, H., Xiao, L., Li, J., Cui, L., Huang, W., Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women, Cochrane Database Syst Rev, 2019. 3(3): p. Cd008018., https://pubmed.ncbi.nlm.nih.gov/30827035/

430. Holoch, P., Wald, M., Current options for preservation of fertility in the male, Fertil Steril, 2011. 96: p. 286-90., https://www.ncbi.nlm.nih.gov/pubmed/21704314

431. Hsiao, W., Stahl, P. J., Osterberg, E. C., Nejat, E., Palermo, G. D., Rosenwaks, Z., et.al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience, J Clin Oncol, 2011. 29: p. 1607-11., https://www.ncbi.nlm.nih.gov/pubmed/21402606

432. Chen, H., Xiao, L., Li, J., Cui, L., Huang, W., Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women, Cochrane Database Syst Rev, 2019. 3(3): p. Cd008018., https://pubmed.ncbi.nlm.nih.gov/30827035/

433. Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., et.al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group, Ann Oncol, 2010. 21: p. 2052-60., https://www.ncbi.nlm.nih.gov/pubmed/20305034

434. Giuseppe, L., Attilio, G., Edoardo, D. N., Loredana, G., Cristina, L., Vincenzo, L., Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD), Hematology, 2007. 12: p. 141-7., https://www.ncbi.nlm.nih.gov/pubmed/17454195

435. Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachee, P., et.al. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial, J Clin Oncol, 2016. 34: p. 2568-74., http://jco.ascopubs.org/content/34/22/2568.full.pdf

436. Del Mastro, L., Boni, L., Michelotti, A., Gamucci, T., Olmeo, N., Gori, S., et.al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial, JAMA, 2011. 306: p. 269-76., https://www.ncbi.nlm.nih.gov/pubmed/21771987

437. Sverrisdottir, A., Nystedt, M., Johansson, H., Fornander, T., Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial, Breast Cancer Res Treat, 2009. 117: p. 561-7., http://www.ncbi.nlm.nih.gov/pubmed/19153828, https://link.springer.com/content/pdf/10.1007%2Fs10549-009-0313-5.pdf

438. Badawy, A., Elnashar, A., El-Ashry, M., Shahat, M., Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study, Fertil Steril, 2009. 91: p. 694-7., https://www.ncbi.nlm.nih.gov/pubmed/18675959

439. Blumenfeld, Z., Avivi, I., Eckman, A., Epelbaum, R., Rowe, J. M., Dann, E. J., Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma, Fertil Steril, 2008. 89: p. 166-73., https://www.ncbi.nlm.nih.gov/pubmed/17601603

440. Castelo-Branco, C., Nomdedeu, B., Camus, A., Mercadal, S., Martinez de Osaba, M. J., Balasch, J., Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy, Fertil Steril, 2007. 87: p. 702-5., https://www.ncbi.nlm.nih.gov/pubmed/17173900

441. Nitzschke, M., Raddatz, J., Bohlmann, M. K., Stute, P., Strowitzki, T., von Wolff, M., GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients, Arch Gynecol Obstet, 2010. 282: p. 83-8., https://link.springer.com/content/pdf/10.1007%2Fs00404-009-1308-5.pdf

442. Huser, M., Crha, I., Ventruba, P., Hudecek, R., Zakova, J., Smardova, L., et.al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients, Hum Reprod, 2008. 23: p. 863-8., http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.545.8632&rep=rep1&type=pdf

443. Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., et.al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial, Annals of Oncology, 2012. 23: p. 1818-25., https://www.ncbi.nlm.nih.gov/pubmed/22228451

444. Blumenfeld, Z., von Wolff, M., GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy, Hum Reprod Update, 2008. 14: p. 543-52., https://www.ncbi.nlm.nih.gov/pubmed/18824495

445. Donnez, J., Dolmans, M. M., Preservation of fertility in females with haematological malignancy, Br J Haematol, 2011. 154: p. 175-84., https://www.ncbi.nlm.nih.gov/pubmed/21564077

446. Donnez, J, Dolmans, MM, Fertility Preservation in Women., N Engl J Med, 2017. 377 (17)(17): p. 1657-1665., https://pubmed.ncbi.nlm.nih.gov/29069558/

447. von Wolff, M., Donnez, J., Hovatta, O., Keros, V., Maltaris, T., Montag, M., et.al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy--a technique in its infancy but already successful in fertility preservation, Eur J Cancer, 2009. 45: p. 1547-53., https://www.ncbi.nlm.nih.gov/pubmed/19264478

448. Lawrenz, B., Henes, M., Neunhoeffer, E., Fehm, T., Lang, P., Schwarze, C. P., Fertility preservation in girls and adolescents before chemotherapy and radiation - review of the literature, Klinische Padiatrie, 2011. 223: p. 126-30., https://www.ncbi.nlm.nih.gov/pubmed/21472633

449. Donnez, J., Dolmans, M. M., Pellicer, A., Diaz-Garcia, C., Sanchez Serrano, M., Schmidt, K. T., et.al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation, Fertil Steril, 2013. 99(6): p. 1503-13., https://pubmed.ncbi.nlm.nih.gov/23635349/

450. Demeestere, I., Simon, P., Emiliani, S., Delbaere, A., Englert, Y., Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease, Oncologist, 2007. 12: p. 1437-42., http://theoncologist.alphamedpress.org/content/12/12/1437.full.pdf

451. Shaw, J. M., Bowles, J., Koopman, P., Wood, E. C., Trounson, A. O., Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients, Hum Reprod, 1996. 11: p. 1668-73., https://www.ncbi.nlm.nih.gov/pubmed/8921114

452. Seshadri, T., Gook, D., Lade, S., Spencer, A., Grigg, A., Tiedemann, K., et.al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield, Br J Cancer, 2006. 94: p. 1007-10., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361234/pdf/94-6603050a.pdf

453. Bittinger, SE, Nazaretian, SP, Gook, DA, Parmar, C, Harrup, RA, Stern, CJ, Detection of Hodgkin lymphoma within ovarian tissue., Fertil Steril, 2011. 95 (2)(2): p. 803.e3-6., https://pubmed.ncbi.nlm.nih.gov/20801440/

454. Meirow, D., Hardan, I., Dor, J., Fridman, E., Elizur, S., Ra'anani, H., et.al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients, Hum Reprod, 2008. 23: p. 1007-13., https://www.ncbi.nlm.nih.gov/pubmed/18344563

455. Holoch, P., Wald, M., Current options for preservation of fertility in the male, Fertil Steril, 2011. 96: p. 286-90., https://www.ncbi.nlm.nih.gov/pubmed/21704314

456. Agarwal, A., Ranganathan, P., Kattal, N., Pasqualotto, F., Hallak, J., Khayal, S., et.al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens, Fertil Steril, 2004. 81: p. 342-8., https://www.ncbi.nlm.nih.gov/pubmed/14967371

457. Bahadur, G., Ling, K. L., Hart, R., Ralph, D., Wafa, R., Ashraf, A., et.al. Semen quality and cryopreservation in adolescent cancer patients, Hum Reprod, 2002. 17: p. 3157-61., https://www.ncbi.nlm.nih.gov/pubmed/12456617

458. Bonetti, T. C., Pasqualotto, F. F., Queiroz, P., Iaconelli, A., Jr., Borges, E., Jr., Sperm banking for male cancer patients: social and semen profiles, Int Braz J Urol, 2009. 35: p. 190-7; discussion 197-8., https://www.ncbi.nlm.nih.gov/pubmed/19409123

459. Chung, K., Irani, J., Knee, G., Efymow, B., Blasco, L., Patrizio, P., Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania, Eur J Obstet Gynecol Reprod Biol, 2004. 113 Suppl 1: p. S7-11., https://www.ncbi.nlm.nih.gov/pubmed/15041122

460. Robertson, J. A., Bonnicksen, A. L., Amato, P., Brzyski, R. G., Damewood, M. D., Greenfeld, D., et.al. Fertility preservation and reproduction in cancer patients, Fertil Steril, 2005. 83: p. 1622-8.

461. Gandini, L., Lombardo, F., Salacone, P., Paoli, D., Anselmo, A. P., Culasso, F., et.al. Testicular cancer and Hodgkin's disease: evaluation of semen quality, Hum Reprod, 2003. 18: p. 796-801., https://www.ncbi.nlm.nih.gov/pubmed/12660273

462. Rueffer, U., Breuer, K., Josting, A., Lathan, B., Sieber, M., Manzke, O., et.al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment, Ann Oncol, 2001. 12: p. 1307-11., https://www.ncbi.nlm.nih.gov/pubmed/11697845

463. Sieniawski, M., Reineke, T., Josting, A., Nogova, L., Behringer, K., Halbsguth, T., et.al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials, Ann Oncol, 2008. 19: p. 1795-801., https://www.ncbi.nlm.nih.gov/pubmed/18544558

464. Viviani, S., Ragni, G., Santoro, A., Perotti, L., Caccamo, E., Negretti, E., et.al. Testicular dysfunction in Hodgkin's disease before and after treatment, Eur J Cancer, 1991. 27: p. 1389-92., https://www.ncbi.nlm.nih.gov/pubmed/1835853

465. Hsiao, W., Stahl, P. J., Osterberg, E. C., Nejat, E., Palermo, G. D., Rosenwaks, Z., et.al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience, J Clin Oncol, 2011. 29: p. 1607-11., https://www.ncbi.nlm.nih.gov/pubmed/21402606

466. Turner, J., Zapart, S., Pedersen, K., Rankin, N., Luxford, K., Fletcher, J., Clinical practice guidelines for the psychosocial care of adults with cancer, Psychooncology, 2005. 14: p. 159-73., http://www.ncbi.nlm.nih.gov/pubmed/15669019

467. Rodin, G., Zimmermann, C., Mayer, C., Howell, D., Katz, M., Sussman, J., et.al. Clinician–patient communication: evidence-based recommendations to guide practice in cancer, Current Oncology, 2009. 16: p. 42-49., https://pmc.ncbi.nlm.nih.gov/articles/PMC2794681/

468. Devine, E. C., Westlake, S. K., The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies, Oncol Nurs Forum, 1995. 22: p. 1369-81., https://www.ncbi.nlm.nih.gov/pubmed/8539178

469. Baile, W. F., Lenzi, R., Kudelka, A. P., Maguire, P., Novack, D., Goldstein, M., et.al. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists, J Cancer Educ, 1997. 12: p. 166-73., https://www.ncbi.nlm.nih.gov/pubmed/9376255

470. Siminoff, L. A., Fetting, J. H., Abeloff, M. D., Doctor-patient communication about breast cancer adjuvant therapy, J Clin Oncol, 1989. 7: p. 1192-200., https://www.ncbi.nlm.nih.gov/pubmed/2671280

471. Luker, K. A., Beaver, K., Leinster, S. J., Owens, R. G., Information needs and sources of information for women with breast cancer: a follow-up study, J Adv Nurs, 1996. 23: p. 487-95., https://www.ncbi.nlm.nih.gov/pubmed/8655823

472. Travis, L. B., Gospodarowicz, M., Curtis, R. E., Clarke, E. A., Andersson, M., Glimelius, B., et.al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease, J Natl Cancer Inst, 2002. 94(3): p. 182-92., https://pubmed.ncbi.nlm.nih.gov/11830608/

473. R, i, c, k, ,, , et.al. Kognitive Dysfunktion bei Krebspatienten, 2017. 20: p. 34 - 37.

474. Kuhnt S, "Fatigue Therapiemanual"Köln, 2017., https://deutsche-fatigue-gesellschaft.de/wp-content/uploads/2017/10/LO_therapie_manual_Ansicht.pdf

475. Kreissl, S., Mueller, H., Goergen, H., Mayer, A., Brillant, C., Behringer, K., et.al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group, Lancet Oncol, 2016. 17(10): p. 1453-1462., https://pubmed.ncbi.nlm.nih.gov/27612583/

476. B, u, n, d, e, s, et.al. 'Rehabilitation. Vom Antrag bis zur Nachsorge - für Aerzte, Psychologische Psychotherapeuten und andere Gesundheitsberufe', Hodgkin Lymphoma., 2018.

477. Cramp, F., Byron-Daniel, J., Exercise for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2012. 11: p. Cd006145., https://pubmed.ncbi.nlm.nih.gov/23152233/

478. Bennett, S., Pigott, A., Beller, E. M., Haines, T., Meredith, P., Delaney, C., Educational interventions for the management of cancer-related fatigue in adults, Cochrane Database Syst Rev, 2016. 11(11): p. Cd008144., https://pubmed.ncbi.nlm.nih.gov/27883365/

479. Mehnert, A., de Boer, A., Feuerstein, M., Employment challenges for cancer survivors, Cancer, 2013. 119 Suppl 11: p. 2151-9., https://pubmed.ncbi.nlm.nih.gov/23695927/

480. Rasmussen, D. M., Elverdam, B., The meaning of work and working life after cancer: an interview study, Psychooncology, 2008. 17(12): p. 1232-8., https://pubmed.ncbi.nlm.nih.gov/18623607/

481. Verbeek, J., Spelten, E., Kammeijer, M., Sprangers, M., Return to work of cancer survivors: a prospective cohort study into the quality of rehabilitation by occupational physicians, Occupational and environmental medicine, 2003. 60(5): p. 352-357., https://pubmed.ncbi.nlm.nih.gov/12709521, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1740540/

482. Mehnert, A., Koch, U., Predictors of employment among cancer survivors after medical rehabilitation--a prospective study, Scand J Work Environ Health, 2013. 39(1): p. 76-87., https://pubmed.ncbi.nlm.nih.gov/22422040/

483. GEKID,, GEKID,, Atlas der Krebsinzidenz und Krebsmortalität der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID). Geschätzte altersspezifische Fallzahlen für Deutschland, 2012.

484. R, o, b, e, r, t, et.al. Krebs in Deutschland 2009/2010, 2013.

485. de Boer, A. G., Verbeek, J. H., Spelten, E. R., Uitterhoeve, A. L., Ansink, A. C., de Reijke, T. M., et.al. Work ability and return-to-work in cancer patients, Br J Cancer, 2008. 98(8): p. 1342-7., https://pubmed.ncbi.nlm.nih.gov/18349834/

486. McGrath, P. D., Hartigan, B., Holewa, H., Skarparis, M., Returning to work after treatment for haematological cancer: findings from Australia, Support Care Cancer, 2012. 20(9): p. 1957-64., https://pubmed.ncbi.nlm.nih.gov/22033835/

487. Roelen, C. A. M., Koopmans, P. C., Groothoff, J. W., van der Klink, J. J. L., Bültmann, U., Return to work after cancer diagnosed in 2002, 2005 and 2008, Journal of occupational rehabilitation, 2011. 21(3): p. 335-341., https://pubmed.ncbi.nlm.nih.gov/21796373, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173615/

488. Buerger W, Buerger W, Positive und gesundheitsförderliche Aspekte der Arbeit und ihre Bedeutung für Patienten in medizinischer Rehabilitation, 1998.

489. Löffler, S., Gerlich, C., Lukasczik, Matthias, Wolf, H. D., Vogel, H., Dr. Neuderth, Silke, Praxishandbuch Arbeits- und berufsbezogene Orientierung in der medizinischen Rehabilitation, 2011.

490. Kähnert, H, Exner, AK, Brand, S, Leibbrand, B., Entwicklung und Bewertung der beruflich-orientierten Intervention “Perspektive Job” für die onkologische Rehabilitation, Rehabilitation, 2016. 55(3): p. 155-156., https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0042-104451

491. Manteuffel, Leonie von, Medizinische Rehabilitation: Berufliche Teilhabe als Leitziel, Dtsch Arztebl International, 2011. 108(4): p. 154-6., https://www.aerzteblatt.de/archiv/medizinische-rehabilitation-berufliche-teilhabe-als-leitziel-4740f195-d636-4270-a3dc-13119e754857

492. Peteet, J. R., Cancer and the meaning of work, Gen Hosp Psychiatry, 2000. 22(3): p. 200-5., https://www.sciencedirect.com/science/article/abs/pii/S0163834300000761

493. Bottcher, H. M., Steimann, M., Rotsch, M., Zurborn, K. H., Koch, U., Bergelt, C., Occupational stress and its association with early retirement and subjective need for occupational rehabilitation in cancer patients, Psychooncology, 2013. 22(8): p. 1807-14., https://onlinelibrary.wiley.com/doi/pdf/10.1002/pon.3224

494. Bottcher, H. M., Steimann, M., Ullrich, A., Rotsch, M., Zurborn, K. H., Koch, U., et.al. Work-related predictors of not returning to work after inpatient rehabilitation in cancer patients, Acta Oncol, 2013. 52(6): p. 1067-75., https://www.tandfonline.com/doi/pdf/10.3109/0284186X.2013.792991?needAccess=true

495. Feuerstein, M., Todd, B. L., Moskowitz, M. C., Bruns, G. L., Stoler, M. R., Nassif, T., et.al. Work in cancer survivors: a model for practice and research, J Cancer Surviv, 2010. 4(4): p. 415-37., https://link.springer.com/content/pdf/10.1007%2Fs11764-010-0154-6.pdf

496. de Boer, A. G., Taskila, T., Ojajarvi, A., van Dijk, F. J., Verbeek, J. H., Cancer survivors and unemployment: a meta-analysis and meta-regression, Jama, 2009. 301(7): p. 753-62., https://jamanetwork.com/journals/jama/articlepdf/183387/jcr90000_753_762.pdf

497. Heim, M, Onkologische Rehabilitation: Wege zurück ins Leben, Hämatologie & Onkologie, 2008. p. 8-12., http://docplayer.org/24025249-Onkologische-rehabilitation-wege-zurueck-ins-leben.html

498. Mehnert, Anja, Härter, Martin, Koch, Uwe, Long-term effects of cancer. Aftercare and rehabilitation requirements, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2012. 55: p. 509-15., https://link.springer.com/content/pdf/10.1007%2Fs00103-012-1447-x.pdf

499. Pryce, J., Munir, F., Haslam, C., Cancer survivorship and work: symptoms, supervisor response, co-worker disclosure and work adjustment, J Occup Rehabil, 2007. 17(1): p. 83-92., https://link.springer.com/content/pdf/10.1007%2Fs10926-006-9040-5.pdf

500. Bartel, Susanne, Return to Work im Spannungsfeld zwischen Erwerbs- und Gesundheitsorientierung, Rehabilitation, 2019. 58(03): p. 172-180., https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-0862-9273.pdf

501. Bürger, Wolfgang, Deck, R., SIBAR – ein kurzes Screening-Instrument zur Messung des Bedarfs an berufsbezogenen Behandlungsangeboten in der medizinischen Rehabilitation, Rehabilitation, 2009. 48: p. 211-221., https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0029-1231062.pdf

502. Sautier, L. P., Scherwath, A., Weis, J., Sarkar, S., Bosbach, M., Schendel, M., et.al. Erfassung von Arbeitsengagement bei Patienten mit hämatologischen Malignomen: Die psychometrischen Eigenschaften der deutschen Version der Utrecht Work Engagement Scale 9 (UWES-9), Rehabilitation, 2015. 54(05): p. 297-303., https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0035-1555912.pdf

503. Mehnert, Anja, Employment and work-related issues in cancer survivors, Critical reviews in oncology/hematology, 2011. 77: p. 109-30., https://www.sciencedirect.com/science/article/abs/pii/S1040842810000053

504. Mehnert, A., Barth, J., Gaspar, M., Leibbrand, B., Kegel, C. D., Bootsveld, W., et.al. Predictors of early retirement after cancer rehabilitation-a longitudinal study, Eur J Cancer Care (Engl), 2016. 26(5):, https://onlinelibrary.wiley.com/doi/pdf/10.1111/ecc.12528

505. Radford, J. A., Eardley, A., Woodman, C., Crowther, D., Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records, BMJ, 1997. 314: p. 343., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2125852/pdf/9040326.pdf

506. Torrey, M. J., Poen, J. C., Hoppe, R. T., Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies, J Clin Oncol, 1997. 15: p. 1123-30., https://www.ncbi.nlm.nih.gov/pubmed/9060554

507. Dryver, E. T., Jernstrom, H., Tompkins, K., Buckstein, R., Imrie, K. R., Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value, Br J Cancer, 2003. 89: p. 482-486., http://dx.doi.org/10.1038/sj.bjc.6601052, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394389/pdf/89-6601052a.pdf

508. Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Linderoth, J., Mylam, K. J., Molin, D., et.al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study, Br J Haematol, 2016. 173: p. 236-44., https://www.ncbi.nlm.nih.gov/pubmed/26846879

509. Radford, J. A., Eardley, A., Woodman, C., Crowther, D., Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records, BMJ, 1997. 314: p. 343., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2125852/pdf/9040326.pdf

510. Torrey, M. J., Poen, J. C., Hoppe, R. T., Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies, J Clin Oncol, 1997. 15: p. 1123-30., https://www.ncbi.nlm.nih.gov/pubmed/9060554

511. Dryver, E. T., Jernstrom, H., Tompkins, K., Buckstein, R., Imrie, K. R., Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value, Br J Cancer, 2003. 89: p. 482-486., https://pubmed.ncbi.nlm.nih.gov/12888816/

512. Basciano, Basciano A., Moskowitz, Craig, Zelenetz, Andrew D., Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma, Blood, 2009. 114: p. 1558-1558.

513. Goldschmidt, N., Or, O., Klein, M., Savitsky, B., Paltiel, O., The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma, Annals of hematology, 2011. 90: p. 165-71., https://www.ncbi.nlm.nih.gov/pubmed/20706721

514. Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Linderoth, J., Mylam, K. J., Molin, D., et.al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study, Br J Haematol, 2016. 173: p. 236-44., https://www.ncbi.nlm.nih.gov/pubmed/26846879

515. Guadagnolo, Beverly A., Punglia, Rinaa S., Kuntz, Karen M., Mauch, Peter M., Ng, Andrea K., Cost-Effectiveness Analysis of Computerized Tomography in the Routine Follow-Up of Patients After Primary Treatment for Hodgkin’s Disease, Journal of Clinical Oncology, 2006. 24: p. 4116-4122., http://jco.ascopubs.org/content/24/25/4116.abstract, http://jco.ascopubs.org/content/24/25/4116.full.pdf

516. Albert, U.-S., Altland, H., Duda, VF., Engel, J., Geraedts, M., Heywang-Köbrunner, S., et.al. Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland 2008, 2008. 79(6): p. 589 - 594., https://doi.org/10.1007/s00104-008-1548-0

517. American Cancer Society, Inc, Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines, 2014., https://www.cancer.org/content/dam/cancer-org/cancer-control/en/reports/complete-systematic-evidence-review-acs-breast-cancer-screening-guideline.pdf

518. Lee, L., Pintilie, M., Hodgson, D. C., Goss, P. E., Crump, M., Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2008. 19: p. 62-7., http://www.ncbi.nlm.nih.gov/pubmed/17878177

519. Howell, S. J., Searle, C., Goode, V., Gardener, T., Linton, K., Cowan, R. A., et.al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage, British journal of cancer, 2009. 101: p. 582-8., http://www.ncbi.nlm.nih.gov/pubmed/19672261, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736813/pdf/6605215a.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736813/pdf/6605215a.pdf

520. Swerdlow, A. J., Cooke, R., Bates, A., Cunningham, D., Falk, S. J., Gilson, D., et.al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study, Journal of Clinical Oncology, 2012. 30: p. 2745-52., https://www.ncbi.nlm.nih.gov/pubmed/22734026

521. Schellong, G., Riepenhausen, M., Ehlert, K., Bramswig, J., Dorffel, W., German Working Group on the Long-Term Sequelae of Hodgkin's, Disease, et.al. Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up, Deutsches Ärzteblatt international, 2014. 111: p. 3-9., https://www.aerzteblatt.de/archiv/152682/Breast-Cancer-in-Young-Women-After-Treatment-for-Hodgkin-s-Disease-During-Childhood-or-Adolescence

522. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., et.al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography, CA: a cancer journal for clinicians, 2007. 57: p. 75-89., http://www.ncbi.nlm.nih.gov/pubmed/17392385

523. Almagro-Casado, E, Sánchez, A, Cantos, B, Salas, C, Pérez-Callejo, D, Provencio, M, Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma., Clin Transl Oncol, 2016. 18 (1)(1): p. 99-106., https://pubmed.ncbi.nlm.nih.gov/26530956/

524. van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., et.al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study, J Clin Oncol, 1994. 12: p. 312-25., https://www.ncbi.nlm.nih.gov/pubmed/8113838

525. Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., et.al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years, J Clin Oncol, 2002. 20: p. 3484-94., https://www.ncbi.nlm.nih.gov/pubmed/12177110

526. Ng, A. K., Bernardo, M. V., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., et.al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors, Blood, 2002. 100: p. 1989-96., https://www.ncbi.nlm.nih.gov/pubmed/12200357

527. Morton, L. M., Dores, G. M., Curtis, R. E., Lynch, C. F., Stovall, M., Hall, P., et.al. Stomach cancer risk after treatment for hodgkin lymphoma, Journal of Clinical Oncology, 2013. 31: p. 3369-77., https://www.ncbi.nlm.nih.gov/pubmed/23980092

528. Franklin, J., Eichenauer, D. A., Becker, I., Monsef, I., Engert, A., Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis, Cochrane Database Syst Rev, 2017. 9: p. Cd008814., https://www.ncbi.nlm.nih.gov/pubmed/28901021

529. Sud, A., Thomsen, H., Sundquist, K., Houlston, R. S., Hemminki, K., Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History, Journal of Clinical Oncology, 2017. 35(14): p. 1584-1590., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med13&AN=28384078

530. Mauch, P. M., Kalish, L. A., Marcus, K. C., Coleman, C. N., Shulman, L. N., Krill, E., et.al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome, Blood, 1996. 87: p. 3625-32., https://www.ncbi.nlm.nih.gov/pubmed/8611686

531. Josting, A., Wiedenmann, S., Franklin, J., May, M., Sieber, M., Wolf, J., et.al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group, J Clin Oncol, 2003. 21: p. 3440-6., https://www.ncbi.nlm.nih.gov/pubmed/12668650

532. Schonfeld, S. J., Gilbert, E. S., Dores, G. M., Lynch, C. F., Hodgson, D. C., Hall, P., et.al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients, J Natl Cancer Inst, 2006. 98: p. 215-8., https://www.ncbi.nlm.nih.gov/pubmed/16449681

533. Franklin, J., Pluetschow, A., Paus, M., Specht, L., Anselmo, A. P., Aviles, A., et.al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials, Ann Oncol, 2006. 17: p. 1749-60., https://www.ncbi.nlm.nih.gov/pubmed/16984979

534. Eichenauer, D. A., Thielen, I., Haverkamp, H., Franklin, J., Behringer, K., Halbsguth, T., et.al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group, Blood, 2014. 123: p. 1658-64., https://www.ncbi.nlm.nih.gov/pubmed/24478403

535. Litzow, M. R., Tarima, S., Perez, W. S., Bolwell, B. J., Cairo, M. S., Camitta, B. M., et.al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia, Blood, 2010. 115: p. 1850-7., http://www.bloodjournal.org/content/bloodjournal/115/9/1850.full.pdf

536. Kayser, S., Dohner, K., Krauter, J., Kohne, C. H., Horst, H. A., Held, G., et.al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood, 2011. 117: p. 2137-45., http://www.bloodjournal.org/content/bloodjournal/117/7/2137.full.pdf

537. Henry-Amar, M., Joly, F., Late complications after Hodgkin's disease, Ann Oncol, 1996. 7 Suppl 4: p. 115-26., https://www.ncbi.nlm.nih.gov/pubmed/8836422

538. Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., et.al. Leukemia following Hodgkin's disease, N Engl J Med, 1990. 322: p. 7-13., https://www.ncbi.nlm.nih.gov/pubmed/2403650

539. Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., Rosenberg, S. A., Risk of second cancers after treatment for Hodgkin's disease, N Engl J Med, 1988. 318: p. 76-81., https://www.ncbi.nlm.nih.gov/pubmed/3336397

540. Swerdlow, A. J., Barber, J. A., Hudson, G. V., Cunningham, D., Gupta, R. K., Hancock, B. W., et.al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment, J Clin Oncol, 2000. 18: p. 498-509., https://www.ncbi.nlm.nih.gov/pubmed/10653865

541. Behringer, K., Josting, A., Schiller, P., Eich, H. T., Bredenfeld, H., Diehl, V., et.al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group, Ann Oncol, 2004. 15: p. 1079-85., https://www.ncbi.nlm.nih.gov/pubmed/15205202

542. Schoenfeld, J. D., Mauch, P. M., Das, P., Silver, B., Marcus, K. J., Stevenson, M. A., et.al. Lung malignancies after Hodgkin lymphoma: disease characteristics, detection methods and clinical outcome, Annals of Oncology, 2012. 23: p. 1813-8., https://www.ncbi.nlm.nih.gov/m/pubmed/22104573/

543. Hodgson, D. C., Koh, E. S., Tran, T. H., Heydarian, M., Tsang, R., Pintilie, M., et.al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma, Cancer, 2007. 110: p. 2576-86., https://www.ncbi.nlm.nih.gov/pubmed/17941006

544. Henderson, T. O., Amsterdam, A., Bhatia, S., Hudson, M. M., Meadows, A. T., Neglia, J. P., et.al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer, Annals of internal medicine, 2010. 152: p. 444-55; W144-54., http://www.ncbi.nlm.nih.gov/pubmed/20368650

545. Hancock, S. L., Tucker, M. A., Hoppe, R. T., Breast cancer after treatment of Hodgkin's disease, Journal of the National Cancer Institute, 1993. 85: p. 25-31., http://www.ncbi.nlm.nih.gov/pubmed/8416252

546. van Leeuwen, F. E., Klokman, W. J., Stovall, M., Dahler, E. C., van't Veer, M. B., Noordijk, E. M., et.al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease, J Natl Cancer Inst, 2003. 95: p. 971-80., https://www.ncbi.nlm.nih.gov/pubmed/12837833

547. Ibrahim, Ezzeldin M., Abouelkhair, Khaled M., Kazkaz, Ghieth A., Elmasri, Osama A., Al-Foheidi, Meteb, Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis, BMC Cancer, 2012. 12: p. 197., http://dx.doi.org/10.1186/1471-2407-12-197

548. Wolden, S. L., Hancock, S. L., Carlson, R. W., Goffinet, D. R., Jeffrey, S. S., Hoppe, R. T., Management of breast cancer after Hodgkin's disease, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000. 18: p. 765-72., http://www.ncbi.nlm.nih.gov/pubmed/10673517, http://jco.ascopubs.org/content/18/4/765.full.pdf

549. Moskowitz, Chaya S., Chou, Joanne F., Wolden, Suzanne L., Bernstein, Jonine L., Malhotra, Jyoti, Novetsky Friedman, Danielle, et.al. Breast cancer after chest radiation therapy for childhood cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. 32(21): p. 2217-2223., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100937/pdf/zlj2217.pdf

550. Swerdlow, A. J., Cooke, R., Bates, A., Cunningham, D., Falk, S. J., Gilson, D., et.al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study, Journal of Clinical Oncology, 2012. 30: p. 2745-52., https://www.ncbi.nlm.nih.gov/pubmed/22734026

551. Hancock, S. L., Tucker, M. A., Hoppe, R. T., Factors affecting late mortality from heart disease after treatment of Hodgkin's disease, JAMA : the journal of the American Medical Association, 1993. 270: p. 1949-55., http://www.ncbi.nlm.nih.gov/pubmed/8411552

552. Franklin, Jeremy, Eichenauer, Dennis, Becker, I., Monsef, Ina, Engert, Andreas, Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survivalJohn Wiley & Sons, Ltd, Cochrane Database of Systematic Reviews, 2016., https://www.ncbi.nlm.nih.gov/pubmed/28901021

553. De Bruin, M. L., Sparidans, J., van't Veer, M. B., Noordijk, E. M., Louwman, M. W., Zijlstra, J. M., et.al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes, J Clin Oncol, 2009. 27: p. 4239-46., https://www.ncbi.nlm.nih.gov/pubmed/19667275

554. Conway, J. L., Connors, J. M., Tyldesley, S., Savage, K. J., Campbell, B. A., Zheng, Y. Y., et.al. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma, International Journal of Radiation Oncology, Biology, Physics, 2017. 97(1): p. 35-41., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med13&AN=27979454

555. van Leeuwen, F. E., Klokman, W. J., Veer, M. B., Hagenbeek, A., Krol, A. D., Vetter, U. A., et.al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood, J Clin Oncol, 2000. 18: p. 487-97., https://www.ncbi.nlm.nih.gov/pubmed/10653864

556. Lee, L., Pintilie, M., Hodgson, D. C., Goss, P. E., Crump, M., Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2008. 19: p. 62-7., http://www.ncbi.nlm.nih.gov/pubmed/17878177

557. Howell, S. J., Searle, C., Goode, V., Gardener, T., Linton, K., Cowan, R. A., et.al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage, British journal of cancer, 2009. 101: p. 582-8., http://www.ncbi.nlm.nih.gov/pubmed/19672261, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736813/pdf/6605215a.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736813/pdf/6605215a.pdf

558. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., et.al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography, CA: a cancer journal for clinicians, 2007. 57: p. 75-89., http://www.ncbi.nlm.nih.gov/pubmed/17392385

559. Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., Friedberg, J., et.al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma, Current problems in cancer, 2010. 34: p. 211-27., http://www.ncbi.nlm.nih.gov/pubmed/20541059

560. Hoppe, Richard T., Advani, Ranjana H., Ai, Weiyun Z., Ambinder, Richard F., Bello, Celeste M., Bierman, Philip J., et.al. Hodgkin Lymphoma, Journal of the National Comprehensive Cancer Network, 2011. 9: p. 1020-1058., http://www.jnccn.org/content/9/9/1020.short, http://www.jnccn.org/content/9/9/1020.full.pdf

561. Schellong, G., Riepenhausen, M., Ehlert, K., Bramswig, J., Dorffel, W., German Working Group on the Long-Term Sequelae of Hodgkin's, Disease, et.al. Breast cancer in young women after treatment for Hodgkin's disease during childhood or adolescence--an observational study with up to 33-year follow-up, Deutsches Ärzteblatt international, 2014. 111: p. 3-9., https://www.aerzteblatt.de/archiv/152682/Breast-Cancer-in-Young-Women-After-Treatment-for-Hodgkin-s-Disease-During-Childhood-or-Adolescence

562. Alm El-Din, M. A., Hughes, K. S., Finkelstein, D. M., Betts, K. A., Yock, T. I., Tarbell, N. J., et.al. Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter, International journal of radiation oncology, biology, physics, 2009. 73: p. 69-74., http://www.ncbi.nlm.nih.gov/pubmed/18538497

563. Warner, E., Messersmith, H., Causer, P., Eisen, A., Shumak, R., Plewes, D., Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer, Annals of internal medicine, 2008. 148: p. 671-9., http://www.ncbi.nlm.nih.gov/pubmed/18458280

564. Ng, A. K., Garber, J. E., Diller, L. R., Birdwell, R. L., Feng, Y., Neuberg, D. S., et.al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma, Journal of Clinical Oncology, 2013. 31: p. 2282-8., https://www.ncbi.nlm.nih.gov/pubmed/23610104

565. Youn, P., Li, H., Milano, M. T., Stovall, M., Constine, L. S., Travis, L. B., Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study, Ann Oncol, 2013. 24(1): p. 202-8., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525132/pdf/mds218.pdf

566. Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., et.al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study, J Natl Cancer Inst, 2007. 99: p. 206-14., https://www.ncbi.nlm.nih.gov/pubmed/17284715

567. Andersson, A., Naslund, U., Tavelin, B., Enblad, G., Gustavsson, A., Malmer, B., Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention, Int J Cancer, 2009. 124: p. 1914-7., https://www.ncbi.nlm.nih.gov/pubmed/19165857

568. Myrehaug, S., Pintilie, M., Yun, L., Crump, M., Tsang, R. W., Meyer, R. M., et.al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease, Blood, 2010. 116: p. 2237-40., http://www.ncbi.nlm.nih.gov/pubmed/20595518, http://bloodjournal.hematologylibrary.org/content/116/13/2237.full.pdf, http://www.bloodjournal.org/content/bloodjournal/116/13/2237.full.pdf

569. Galper, S. L., Yu, J. B., Mauch, P. M., Strasser, J. F., Silver, B., Lacasce, A., et.al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation, Blood, 2011. 117: p. 412-8., http://www.ncbi.nlm.nih.gov/pubmed/20858859, http://bloodjournal.hematologylibrary.org/content/117/2/412.full.pdf, http://www.bloodjournal.org/content/bloodjournal/117/2/412.full.pdf

570. van Leeuwen, F. E., Ng, A. K., Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment, Hematology Am Soc Hematol Educ Program, 2016. 2016: p. 323-330., http://asheducationbook.hematologylibrary.org/content/2016/1/323.long?hw-tma-check=true

571. Kupeli, S., Hazirolan, T., Varan, A., Akata, D., Alehan, D., Hayran, M., et.al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma, J Clin Oncol, 2009. 28: p. 1025-30., https://www.ncbi.nlm.nih.gov/pubmed/20038721

572. Kleikamp, G., Schnepper, U., Korfer, R., Coronary artery and aortic valve disease as a long-term sequel of mediastinal and thoracic irradiation, The Thoracic and cardiovascular surgeon, 1997. 45: p. 27-31., http://www.ncbi.nlm.nih.gov/pubmed/9089971, https://www.thieme-connect.com/ejournals/pdf/thoracic/doi/10.1055/s-2007-1013679.pdf, https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-2007-1013679.pdf

573. Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., et.al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease, J Clin Oncol, 2007. 25: p. 43-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17194904, http://jco.ascopubs.org/content/25/1/43.full.pdf

574. Aviles, A., Neri, N., Nambo, J. M., Huerta-Guzman, J., Talavera, A., Cleto, S., Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy, Leuk Lymphoma, 2005. 46: p. 1023-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16019553, http://informahealthcare.com/doi/pdfplus/10.1080/10428190500063229, http://www.tandfonline.com/doi/pdf/10.1080/10428190500063229?needAccess=true

575. Heidenreich, P. A., Hancock, S. L., Vagelos, R. H., Lee, B. K., Schnittger, I., Diastolic dysfunction after mediastinal irradiation, American heart journal, 2005. 150: p. 977-82., http://www.ncbi.nlm.nih.gov/pubmed/16290974

576. Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., et.al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study, J Natl Cancer Inst, 2007. 99: p. 206-14., https://www.ncbi.nlm.nih.gov/pubmed/17284715

577. Andersson, A., Naslund, U., Tavelin, B., Enblad, G., Gustavsson, A., Malmer, B., Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention, Int J Cancer, 2009. 124: p. 1914-7., https://www.ncbi.nlm.nih.gov/pubmed/19165857

578. Myrehaug, S., Pintilie, M., Yun, L., Crump, M., Tsang, R. W., Meyer, R. M., et.al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease, Blood, 2010. 116: p. 2237-40., http://www.ncbi.nlm.nih.gov/pubmed/20595518, http://bloodjournal.hematologylibrary.org/content/116/13/2237.full.pdf, http://www.bloodjournal.org/content/bloodjournal/116/13/2237.full.pdf

579. Galper, S. L., Yu, J. B., Mauch, P. M., Strasser, J. F., Silver, B., Lacasce, A., et.al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation, Blood, 2011. 117: p. 412-8., http://www.ncbi.nlm.nih.gov/pubmed/20858859, http://bloodjournal.hematologylibrary.org/content/117/2/412.full.pdf, http://www.bloodjournal.org/content/bloodjournal/117/2/412.full.pdf

580. van Leeuwen, F. E., Ng, A. K., Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment, Hematology Am Soc Hematol Educ Program, 2016. 2016: p. 323-330., http://asheducationbook.hematologylibrary.org/content/2016/1/323.long?hw-tma-check=true

581. Aviles, A., Neri, N., Nambo, J. M., Huerta-Guzman, J., Talavera, A., Cleto, S., Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy, Leuk Lymphoma, 2005. 46: p. 1023-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16019553, http://informahealthcare.com/doi/pdfplus/10.1080/10428190500063229, http://www.tandfonline.com/doi/pdf/10.1080/10428190500063229?needAccess=true

582. Heidenreich, P. A., Hancock, S. L., Vagelos, R. H., Lee, B. K., Schnittger, I., Diastolic dysfunction after mediastinal irradiation, American heart journal, 2005. 150: p. 977-82., http://www.ncbi.nlm.nih.gov/pubmed/16290974

583. Hull, M. C., Morris, C. G., Pepine, C. J., Mendenhall, N. P., Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy, JAMA : the journal of the American Medical Association, 2003. 290: p. 2831-7., http://www.ncbi.nlm.nih.gov/pubmed/14657067, http://jama.ama-assn.org/content/290/21/2831.full.pdf, http://jama.jamanetwork.com/data/journals/jama/4906/joc30720.pdf

584. Adams, M. J., Lipsitz, S. R., Colan, S. D., Tarbell, N. J., Treves, S. T., Diller, L., et.al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004. 22: p. 3139-48., http://www.ncbi.nlm.nih.gov/pubmed/15284266, http://jco.ascopubs.org/content/22/15/3139.full.pdf

585. Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M., Chen, Z., et.al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy, Leuk Lymphoma, 2008. 49: p. 1486-93., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18608873, http://informahealthcare.com/doi/pdfplus/10.1080/10428190802140873, http://www.tandfonline.com/doi/pdf/10.1080/10428190802140873?needAccess=true

586. Cutter, D. J., Schaapveld, M., Darby, S. C., Hauptmann, M., Nimwegen, F. A., Krol, A. D. G., et.al. Risk for valvular heart disease after treatment for hodgkin lymphoma, Journal of the National Cancer Institute, 2015., https://www.ncbi.nlm.nih.gov/pubmed/25713164

587. Mauch, P. M., Kalish, L. A., Marcus, K. C., Shulman, L. N., Krill, E., Tarbell, N. J., et.al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease, The cancer journal from Scientific American, 1995. 1: p. 33-42., http://www.ncbi.nlm.nih.gov/pubmed/9166452

588. Lee, C. K., Aeppli, D., Nierengarten, M. E., The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience, International journal of radiation oncology, biology, physics, 2000. 48: p. 169-79., http://www.ncbi.nlm.nih.gov/pubmed/10924987

589. Reinders, J. G., Heijmen, B. J., Olofsen-van Acht, M. J., van Putten, W. L., Levendag, P. C., Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1999. 51: p. 35-42., http://www.ncbi.nlm.nih.gov/pubmed/10386715

590. van Nimwegen, FA, Ntentas, G, Darby, SC, Schaapveld, M, Hauptmann, M, Lugtenburg, PJ, et.al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines., Blood, 2017. 129 (16)(16): p. 2257-2265., https://pubmed.ncbi.nlm.nih.gov/28143884/

591. Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., et.al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort, BMJ, 2009. 339: p. b4606., http://www.ncbi.nlm.nih.gov/pubmed/19996459

592. Kupeli, S., Hazirolan, T., Varan, A., Akata, D., Alehan, D., Hayran, M., et.al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma, J Clin Oncol, 2009. 28: p. 1025-30., https://www.ncbi.nlm.nih.gov/pubmed/20038721

593. Maraldo, MV, Giusti, F, Vogelius, IR, Lundemann, M, van der Kaaij, MA, Ramadan, S, et.al. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials., Lancet Haematol, 2015. 2 (11)(11): p. e492-502., https://pubmed.ncbi.nlm.nih.gov/26686259/

594. Kleikamp, G., Schnepper, U., Korfer, R., Coronary artery and aortic valve disease as a long-term sequel of mediastinal and thoracic irradiation, The Thoracic and cardiovascular surgeon, 1997. 45: p. 27-31., http://www.ncbi.nlm.nih.gov/pubmed/9089971

595. Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., et.al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease, J Clin Oncol, 2007. 25: p. 43-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17194904, http://jco.ascopubs.org/content/25/1/43.full.pdf

596. King, V., Constine, L. S., Clark, D., Schwartz, R. G., Muhs, A. G., Henzler, M., et.al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease, International journal of radiation oncology, biology, physics, 1996. 36: p. 881-9., http://www.ncbi.nlm.nih.gov/pubmed/8960517

597. Wethal, T., Lund, M. B., Edvardsen, T., Fossa, S. D., Pripp, A. H., Holte, H., et.al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study, British journal of cancer, 2009. 101: p. 575-81., http://www.ncbi.nlm.nih.gov/pubmed/19623176, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736805/pdf/6605191a.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736805/pdf/6605191a.pdf

598. Bethge, W., Guggenberger, D., Bamberg, M., Kanz, L., Bokemeyer, C., Thyroid toxicity of treatment for Hodgkin's disease, Ann Hematol, 2000. 79: p. 114-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10803932

599. Illes, A., Biro, E., Miltenyi, Z., Keresztes, K., Varoczy, L., Andras, C., et.al. Hypothyroidism and thyroiditis after therapy for Hodgkin's disease, Acta haematologica, 2003. 109: p. 11-7., http://www.ncbi.nlm.nih.gov/pubmed/12486317

600. Hancock, S. L., Cox, R. S., McDougall, I. R., Thyroid diseases after treatment of Hodgkin's disease, N Engl J Med, 1991. 325: p. 599-605., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1861693, http://www.nejm.org/doi/pdf/10.1056/NEJM199108293250902

601. Hancock, S. L., Cox, R. S., McDougall, I. R., Thyroid diseases after treatment of Hodgkin's disease, N Engl J Med, 1991. 325: p. 599-605., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1861693, http://www.nejm.org/doi/pdf/10.1056/NEJM199108293250902

602. Bethge, W., Guggenberger, D., Bamberg, M., Kanz, L., Bokemeyer, C., Thyroid toxicity of treatment for Hodgkin's disease, Ann Hematol, 2000. 79: p. 114-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10803932

603. Illes, A., Biro, E., Miltenyi, Z., Keresztes, K., Varoczy, L., Andras, C., et.al. Hypothyroidism and thyroiditis after therapy for Hodgkin's disease, Acta haematologica, 2003. 109: p. 11-7., http://www.ncbi.nlm.nih.gov/pubmed/12486317

604. Michaelson, Evan M., Chen, Yu-Hui, Silver, Barbara, Tishler, Roy B., Marcus, Karen J., Stevenson, Mary Ann, et.al. Thyroid Malignancies in Survivors of Hodgkin Lymphoma, International Journal of Radiation Oncology*Biology*Physics, 2014. 88: p. 636-641., http://www.sciencedirect.com/science/article/pii/S0360301613035980

605. Ng, A. K., Li, S., Neuberg, D., Chi, R., Fisher, D. C., Silver, B., et.al. A prospective study of pulmonary function in Hodgkin's lymphoma patients, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2008. 19: p. 1754-8., http://www.ncbi.nlm.nih.gov/pubmed/18467315

606. Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., Ansell, S. M., Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005. 23: p. 7614-20., http://www.ncbi.nlm.nih.gov/pubmed/16186594, http://jco.ascopubs.org/content/23/30/7614.full.pdf

607. Villani, F., Viola, G., Vismara, C., Laffranchi, A., Di Russo, A., Viviani, S., et.al. Lung function and serum concentrations of different cytokines in patients submitted to radiotherapy and intermediate/high dose chemotherapy for Hodgkin's disease, Anticancer research, 2002. 22: p. 2403-8., http://www.ncbi.nlm.nih.gov/pubmed/12174934

608. Ng, A. K., Li, S., Neuberg, D., Chi, R., Fisher, D. C., Silver, B., et.al. A prospective study of pulmonary function in Hodgkin's lymphoma patients, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2008. 19: p. 1754-8., http://www.ncbi.nlm.nih.gov/pubmed/18467315

609. Martin, W. G., Ristow, K. M., Habermann, T. M., Colgan, J. P., Witzig, T. E., Ansell, S. M., Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005. 23: p. 7614-20., http://www.ncbi.nlm.nih.gov/pubmed/16186594, http://jco.ascopubs.org/content/23/30/7614.full.pdf

610. Hirsch, A., Vander Els, N., Straus, D. J., Gomez, E. G., Leung, D., Portlock, C. S., et.al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996. 14: p. 1297-305., http://www.ncbi.nlm.nih.gov/pubmed/8648387, http://jco.ascopubs.org/content/14/4/1297.full.pdf

611. Madabhavi, I, Modi, G, Patel, A, Anand, A, Panchal, H, Parikh, S, Pulmonary toxicity following bleomycin use: A single-center experience., J Cancer Res Ther 13 (3)(3): p. 466-470., https://pubmed.ncbi.nlm.nih.gov/28862210/

612. Sleijfer, S., Bleomycin-induced pneumonitis, Chest, 2001. 120: p. 617-24., http://www.ncbi.nlm.nih.gov/pubmed/11502668, http://chestjournal.chestpubs.org/content/120/2/617.full.pdf

613. Horning, S. J., Adhikari, A., Rizk, N., Hoppe, R. T., Olshen, R. A., Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994. 12: p. 297-305., http://www.ncbi.nlm.nih.gov/pubmed/7509383, http://jco.ascopubs.org/content/12/2/297.full.pdf

614. Sun, HL, Atenafu, EG, Tsang, R, Kukreti, V, Marras, TK, Crump, M, et.al. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma., Leuk Lymphoma, 2017. 58 (11)(11): p. 2607-2614., https://pubmed.ncbi.nlm.nih.gov/28504035/

615. Franchi-Rezgui, P., Rousselot, P., Espie, M., Briere, J., Pierre Marolleau, J., Gisselbrecht, C., et.al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas, Hematol J, 2003. 4: p. 116-20., https://europepmc.org/abstract/med/12750730

616. Haukvik, U. K., Dieset, I., Bjoro, T., Holte, H., Fossa, S. D., Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma, Ann Oncol, 2006. 17: p. 1428-33., http://annonc.oxfordjournals.org/content/17/9/1428.full.pdf

617. De Bruin, M. L., Huisbrink, J., Hauptmann, M., Kuenen, M. A., Ouwens, G. M., van't Veer, M. B., et.al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma, Blood, 2008. 111: p. 101-8., http://bloodjournal.hematologylibrary.org/content/111/1/101.full.pdf, http://www.bloodjournal.org/content/bloodjournal/111/1/101.full.pdf

618. van der Kaaij, M. A., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E. C., et.al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study, Journal of Clinical Oncology, 2012. 30: p. 291-9., https://www.ncbi.nlm.nih.gov/pubmed/22184372

619. Baxter, N. N., Sutradhar, R., DelGuidice, M. E., Forbes, S., Paszat, L. F., Wilton, A. S., et.al. A population-based study of rates of childbirth in recurrence-free female young adult survivors of non-gynecologic malignancies, BMC Cancer, 2013. 13: p. 30., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23343211, http://www.digibib.net/openurl/038?&sid=OVID:medline&id=pmid:23343211&id=doi:10.1186%2F1471-2407-13-30&issn=1471-2407&isbn=&volume=13&issue=1&spage=30&pages=30&date=2013&title=BMC+Cancer&atitle=A+population-based+study+of+rates+of+childbirth+in+recurrence-free+female+young+adult+survivors+of+non-gynecologic+malignancies.&aulast=Baxter&pid=%3Cauthor%3EBaxter+NN%3BSutradhar+R%3BDelGuidice+ME%3BForbes+S%3BPaszat+LF%3BWilton+AS%3BUrbach+D%3BRabeneck+L%3C%2Fauthor%3E%3CAN%3E23343211%3C%2FAN%3E%3CDT%3EJournal+Article%3C%2FDT%3E, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605316/pdf/1471-2407-13-30.pdf

620. van der Kaaij, M. A., van Echten-Arends, J., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., et.al. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study, Human Reproduction, 2014. 29: p. 525-33., https://www.ncbi.nlm.nih.gov/pubmed/24345581

621. Bramswig, J. H., Riepenhausen, M., Schellong, G., Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study, Lancet Oncol, 2015. 16: p. 667-75., http://ac.els-cdn.com/S1470204515701403/1-s2.0-S1470204515701403-main.pdf?_tid=d8ce0e9c-4534-11e7-9ec7-00000aab0f02&acdnat=1496148073_1c1bf74c4e9d94281cfb8aa91ee207f4

622. Anderson, Richard A, Remedios, Rachel, Kirkwood, Amy A, Patrick, Pip, Stevens, Linsey, Clifton-Hadley, Laura, et.al. Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trialElsevier, The Lancet Oncology, 2018. 19(10): p. 1328 - 1337., https://doi.org/10.1016/S1470-2045(18)30500-X

623. Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., et.al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group, J Clin Oncol, 2005. 23: p. 7555-64., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16234521, http://jco.ascopubs.org/content/23/30/7555.full.pdf

624. Falorio, S., Biasoli, I., Luminari, S., Quintana, G., Musso, M., Dell'olio, M., et.al. Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions, Hematol Oncol, 2013. 31: p. 72-8., https://www.ncbi.nlm.nih.gov/pubmed/23027689

625. Letourneau, J. M., Ebbel, E. E., Katz, P. P., Oktay, K. H., McCulloch, C. E., Ai, W. Z., et.al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer, Cancer, 2012. 118: p. 1933-9., https://www.ncbi.nlm.nih.gov/pubmed/21850728

626. Kiserud, C. E., Fossa, A., Bjoro, T., Holte, H., Cvancarova, M., Fossa, S. D., Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy, Br J Cancer, 2009. 100: p. 455-63., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19156143, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658535/pdf/6604892a.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658535/pdf/6604892a.pdf

627. Baxter, N. N., Sutradhar, R., DelGuidice, M. E., Forbes, S., Paszat, L. F., Wilton, A. S., et.al. A population-based study of rates of childbirth in recurrence-free female young adult survivors of non-gynecologic malignancies, BMC Cancer, 2013. 13: p. 30., http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=23343211, http://www.digibib.net/openurl/038?&sid=OVID:medline&id=pmid:23343211&id=doi:10.1186%2F1471-2407-13-30&issn=1471-2407&isbn=&volume=13&issue=1&spage=30&pages=30&date=2013&title=BMC+Cancer&atitle=A+population-based+study+of+rates+of+childbirth+in+recurrence-free+female+young+adult+survivors+of+non-gynecologic+malignancies.&aulast=Baxter&pid=%3Cauthor%3EBaxter+NN%3BSutradhar+R%3BDelGuidice+ME%3BForbes+S%3BPaszat+LF%3BWilton+AS%3BUrbach+D%3BRabeneck+L%3C%2Fauthor%3E%3CAN%3E23343211%3C%2FAN%3E%3CDT%3EJournal+Article%3C%2FDT%3E, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605316/pdf/1471-2407-13-30.pdf

628. Howell, S. J., Shalet, S. M., Testicular function following chemotherapy, Hum Reprod Update, 2001. 7: p. 363-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11476348, http://humupd.oxfordjournals.org/content/7/4/363.full.pdf

629. Kiserud, C. E., Fossa, A., Holte, H., Fossa, S. D., Post-treatment parenthood in Hodgkin's lymphoma survivors, Br J Cancer, 2007. 96: p. 1442-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17406362, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360165/pdf/6603711a.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360165/pdf/6603711a.pdf

630. Paoli, D, Rizzo, F, Fiore, G, Pallotti, F, Pulsoni, A, Annechini, G, et.al. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens., Hum Reprod, 2016. 31 (2)(2): p. 263-72., https://pubmed.ncbi.nlm.nih.gov/26705149/

631. Kulkarni, S. S., Sastry, P. S., Saikia, T. K., Parikh, P. M., Gopal, R., Advani, S. H., Gonadal function following ABVD therapy for Hodgkin's disease, Am J Clin Oncol, 1997. 20: p. 354-7., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9256888

632. Kiserud, C. E., Fossa, A., Bjoro, T., Holte, H., Cvancarova, M., Fossa, S. D., Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy, Br J Cancer, 2009. 100: p. 455-63., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19156143, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658535/pdf/6604892a.pdf, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658535/pdf/6604892a.pdf

633. Bramswig, J. H., Riepenhausen, M., Schellong, G., Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study, Lancet Oncol, 2015. 16: p. 667-75., http://ac.els-cdn.com/S1470204515701403/1-s2.0-S1470204515701403-main.pdf?_tid=d8ce0e9c-4534-11e7-9ec7-00000aab0f02&acdnat=1496148073_1c1bf74c4e9d94281cfb8aa91ee207f4

634. Ash, P., The influence of radiation on fertility in man, Br J Radiol, 1980. 53: p. 271-8., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6991051

635. Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibi, A. S., Rosenbrock, J., Fertlity and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial, Annals of Oncology, 2012. p. 1818-25., http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/402/CN-00853402/frame.html

636. Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., et.al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group, J Clin Oncol, 2005. 23: p. 7555-64., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16234521, http://jco.ascopubs.org/content/23/30/7555.full.pdf

637. Franchi-Rezgui, P., Rousselot, P., Espie, M., Briere, J., Pierre Marolleau, J., Gisselbrecht, C., et.al. Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas, Hematol J, 2003. 4: p. 116-20., https://europepmc.org/abstract/med/12750730

638. Haukvik, U. K., Dieset, I., Bjoro, T., Holte, H., Fossa, S. D., Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma, Ann Oncol, 2006. 17: p. 1428-33., http://annonc.oxfordjournals.org/content/17/9/1428.full.pdf

639. De Bruin, M. L., Huisbrink, J., Hauptmann, M., Kuenen, M. A., Ouwens, G. M., van't Veer, M. B., et.al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma, Blood, 2008. 111: p. 101-8., http://bloodjournal.hematologylibrary.org/content/111/1/101.full.pdf, http://www.bloodjournal.org/content/bloodjournal/111/1/101.full.pdf

640. van der Kaaij, M. A., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E. C., et.al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study, Journal of Clinical Oncology, 2012. 30: p. 291-9., https://www.ncbi.nlm.nih.gov/pubmed/22184372

641. Falorio, S., Biasoli, I., Luminari, S., Quintana, G., Musso, M., Dell'olio, M., et.al. Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions, Hematol Oncol, 2013. 31: p. 72-8., https://www.ncbi.nlm.nih.gov/pubmed/23027689

642. Letourneau, J. M., Ebbel, E. E., Katz, P. P., Oktay, K. H., McCulloch, C. E., Ai, W. Z., et.al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer, Cancer, 2012. 118: p. 1933-9., https://www.ncbi.nlm.nih.gov/pubmed/21850728

643. van der Kaaij, M. A., van Echten-Arends, J., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., et.al. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study, Human Reproduction, 2014. 29: p. 525-33., https://www.ncbi.nlm.nih.gov/pubmed/24345581

644. Daniels, L. A., Oerlemans, S., Krol, A. D., van de Poll-Franse, L. V., Creutzberg, C. L., Persisting fatigue in Hodgkin lymphoma survivors: a systematic review, Annals of Hematology, 2013. 92: p. 1023-32., https://www.ncbi.nlm.nih.gov/pubmed/23728609

645. Daniels, L. A., Oerlemans, S., Krol, A. D., Creutzberg, C. L., van de Poll-Franse, L. V., Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity, British journal of cancer, 2014. 110: p. 868-74., https://www.ncbi.nlm.nih.gov/pubmed/24434433

646. Kreissl, S., Mueller, H., Goergen, H., Mayer, A., Brillant, C., Behringer, K., et.al. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group, Lancet Oncol, 2016. 17: p. 1453-1462., https://www.ncbi.nlm.nih.gov/pubmed/27612583

647. Behringer, K., Goergen, H., Muller, H., Thielen, I., Brillant, C., Kreissl, S., et.al. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration, J Clin Oncol, 2016. 34: p. 4329-4337., https://www.ncbi.nlm.nih.gov/pubmed/27998235

648. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF),, Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten, Langversion 1.1, AWMF-Registernummer: 032/051OL, 2014., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie/

649. Berger, AM, Abernethy, AP, Atkinson, A, Barsevick, AM, Breitbart, WS, Cella, D, et.al. NCCN Clinical Practice Guidelines Cancer-related fatigue., J Natl Compr Canc Netw, 2010. 8 (8)(8): p. 904-31., https://pubmed.ncbi.nlm.nih.gov/20870636/

650. Loge, J. H., Abrahamsen, A. F., Ekeberg, O., Kaasa, S., Hodgkin's disease survivors more fatigued than the general population, J Clin Oncol, 1999. 17: p. 253-61., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10458240, http://jco.ascopubs.org/content/17/1/253.full.pdf

651. Fobair, P., Hoppe, R. T., Bloom, J., Cox, R., Varghese, A., Spiegel, D., Psychosocial problems among survivors of Hodgkin's disease, J Clin Oncol, 1986. 4: p. 805-14., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3486256, http://jco.ascopubs.org/content/4/5/805.full.pdf

652. Roper, K., McDermott, K., Cooley, M. E., Daley, K., Fawcett, J., Health-related quality of life in adults with Hodgkin's disease: the state of the science, Cancer nursing, 2009. 32: p. E1-17; quiz E18-9., http://www.ncbi.nlm.nih.gov/pubmed/19816166, https://insights.ovid.com/pubmed?pmid=19816166

653. Ruffer, J. U., Flechtner, H., Tralls, P., Josting, A., Sieber, M., Lathan, B., et.al. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG), Eur J Cancer, 2003. 39: p. 2179-86., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14522376, http://ac.els-cdn.com/S0959804903005458/1-s2.0-S0959804903005458-main.pdf?_tid=e6fce8f8-4d2c-11e7-8450-00000aacb362&acdnat=1497024270_0f553c1d0e2121bde5924259c42954a7

654. Daniels, L. A., Oerlemans, S., Krol, A. D., van de Poll-Franse, L. V., Creutzberg, C. L., Persisting fatigue in Hodgkin lymphoma survivors: a systematic review, Annals of Hematology, 2013. 92: p. 1023-32., https://www.ncbi.nlm.nih.gov/pubmed/23728609

655. Behringer, K., Goergen, H., Muller, H., Thielen, I., Brillant, C., Kreissl, S., et.al. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration, J Clin Oncol, 2016. 34: p. 4329-4337., https://www.ncbi.nlm.nih.gov/pubmed/27998235

656. Ganz, P. A., Moinpour, C. M., Pauler, D. K., Kornblith, A. B., Gaynor, E. R., Balcerzak, S. P., et.al. Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133, J Clin Oncol, 2003. 21: p. 3512-9., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12972528, http://jco.ascopubs.org/content/21/18/3512.full.pdf

657. Heutte, N., Flechtner, H. H., Mounier, N., Mellink, W. A., Meerwaldt, J. H., Eghbali, H., et.al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial, Lancet Oncol, 2009. 10: p. 1160-70., http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19828373, http://ac.els-cdn.com/S147020450970258X/1-s2.0-S147020450970258X-main.pdf?_tid=62494b42-4d2c-11e7-8735-00000aacb362&acdnat=1497024048_27176fe0325f73e2447ed2a2799770e6

658. Howell, D., Keller-Olaman, S., Oliver, T. K., Hack, T. F., Broadfield, L., Biggs, K., et.al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue, Curr Oncol, 2013. 20(3): p. e233-46., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671030/

659. McNeely, M. L., Courneya, K. S., Exercise programs for cancer-related fatigue: evidence and clinical guidelines, Journal of the National Comprehensive Cancer Network : JNCCN, 2010. 8: p. 945-53., http://www.ncbi.nlm.nih.gov/pubmed/20870638, http://www.jnccn.org/content/8/8/945.long

660. Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et.al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 2008. 336: p. 924-6., https://www.ncbi.nlm.nih.gov/pubmed/18436948

661. Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., et.al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias), J Clin Epidemiol, 2011. 64: p. 407-15., https://www.ncbi.nlm.nih.gov/pubmed/21247734

662. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency, J Clin Epidemiol, 2011. 64: p. 1294-302., https://www.ncbi.nlm.nih.gov/pubmed/21803546

663. Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., et.al. GRADE guidelines 6. Rating the quality of evidence--imprecision, J Clin Epidemiol, 2011. 64: p. 1283-93., https://www.ncbi.nlm.nih.gov/pubmed/21839614

664. Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et.al. GRADE guidelines: 8. Rating the quality of evidence--indirectness, J Clin Epidemiol, 2011. 64: p. 1303-10., https://www.ncbi.nlm.nih.gov/pubmed/21802903

665. Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., et.al. GRADE guidelines: 5. Rating the quality of evidence--publication bias, J Clin Epidemiol, 2011. 64: p. 1277-82., https://www.ncbi.nlm.nih.gov/pubmed/21802904

666. Balshem, H., Helfand, M., Schunemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., et.al. GRADE guidelines: 3. Rating the quality of evidence, J Clin Epidemiol, 2011. 64: p. 401-6., https://www.ncbi.nlm.nih.gov/pubmed/21208779